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 I 
Abstract 
Porcine circovirus type 2 (PCV2) has been identified as the main causative agent of the 
postweaning multisystemic wasting syndrome (PMWS), one of the major swine diseases 
worldwide that is commonly referred, together with other relevant porcine diseases related to 
PCV2, as belonging to the porcine circovirus associated diseases (PCVD). 
The most important strategy to prevent and control PCV2 associated diseases, apart from 
management procedures and control of coinfections, is the vaccination of piglets or sows and 
gilts. Nowadays there are three commercial PCV2 vaccines available; even if their efficacy in 
reducing the viremia burden and viral-induced specific lymphoid lesions has been proved, the 
mechanisms by which they are able to elicit protective immunity have not been thoroughly 
clarified. Besides the development of humoral immunity that is generally characterised by the 
detection of total anti-PCV2 and virus-neutralizing antibodies, the mechanisms that allow the 
adaptive cell-mediated immune response to control PCV2 infection and the related diseases 
have not been clearly elucidated, particularly under field conditions. 
The present Thesis investigated the efficacy of a one-dose porcine circovirus 2 (PCV2) 
subunit vaccine based on the PCV2 Cap protein expressed in a baculovirus system in two 
different farms (farm1 and 2) at which a history of porcine circovirus-associated disease 
(PCVD) was present. Morbidity, mortality, average daily weight gain, carcass weight, PCV2 
load in serum and vaccine immunogenicity, in terms of PCV2-specific antibodies,                   
PCV2-specific IFN-γ secreting cell frequencies and mRNA expression profiles of relevant 
pro-inflammatory and immune cytokines, were assessed. Serology to potential coinfections 
due to porcine reproductive and respiratory syndrome virus (PRRSV) and                        
Mycoplasma hyopneumoniae (M. hyo.) was also carried out.  
A double-blind, randomised, and controlled field trial was performed distributing 818 piglets 
in two treatment groups. At inclusion (weaning at 21±3 days of age), 408 animals received a 
2-ml intramuscular dose of Porcilis PCV® (vaccinated group) suspended in a tocopherol-based 
adjuvant (Diluvac Forte®). Controls (410 piglets) received 2 ml of the same adjuvant alone 
intramuscularly. Weights were recorded at inclusion and at 12 and 26 weeks of age, and the 
average daily weight gain (ADWG) was calculated. The carcass weights of the pigs from farm 
2 were recorded at slaughter (274 day-old pigs). All dead animals (died or culled) underwent 
autopsy to classify them as PMWS-affected or not. At each farm, blood samples were 
collected for serologic and cellular studies aimed at investigating the humoral                          
(ELISA determination of PCV2-antibody titres in serum) and cell-mediated (ELISpot assay 
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for the measurement of the PCV2-specific IFN-γ secreting cell frequencies in PBMC) 
immune response of pigs.  
The analyses of the present Thesis showed that vaccination with a single dose of a PCV2 Cap 
vaccine had beneficial effects against the PCVD, and especially PMWS. The vaccination 
reduced the mortality rate and morbidity, PCV2 viremia and viral load, and improved 
productive performances (e.g. ADWG: +70 g/day between 12 and 26 weeks of age when 
viremia and the specific disease occurred) as well as carcass weight at slaughter age                        
(+4.5 kg). These effects were associated with virologic and clinical protection derived from 
the immunogenicity of the vaccine measured as activation of both humoral and a cellular 
immune responses. In this regard, ELISA quantification of PCV2-specific antibodies showed 
seroconversion (with exception of pigs with a titre of maternally derived antibodies >8 log2) 
and long lasting protective immunity in all vaccinated pigs. Furthermore, the increased 
frequency of IFN-γ secreting cells that was detected by the ELISpot assay during the                   
post-vaccination period demonstrated the capability of a single dose of the PCV2 Cap-based 
vaccine to induce a virus-specific cell-mediated immune response. During the post-exposure 
period, vaccinated animals rapidly and efficiently counteracted virus spread since both 
humoral and cell-mediated immunity were associated with absent or low viremia and less 
severe clinical signs.  
In addition, in order to obtain more thorough information about the mechanisms of cellular 
immune reactivity, the evaluation of expression patterns of relevant pro-inflammatory               
(IL-8, TNF-α, IL-1β) and immune (IFN-γ, IL-10) cytokines was carried out.  
Cytokine modulation and course of viremia were assessed in 10 PCV2-vaccinated and                                      
20 non-vaccinated pigs from farm 1. These analyses were performed by reverse 
transcriptional-quantitative PCR (RT-qPCR) before the onset of PCV2 viremia (16 weeks of 
age), upon PCV2 infection and after the onset of PMWS clinical signs (19 and 22 weeks of 
age, respectively). The cytokine response was evaluated with regards to evident clinical signs 
related to PMWS and course of viremia, grouping the animals into three groups: 1) vaccinated 
(PCV2-vac) pigs; 2) unvaccinated spontaneously infected/non-PMWS-affected (Ctrl) pigs;             
3) unvaccinated spontaneously infected/PMWS-affected (Ctrl-PMWS+) pigs.  
Moreover, in order to establish an association between cytokine expression and viremia 
burden, each of the above mentionated groups was analysed dividing the animals in three 
different subgroups based on viremia: non-viremic pigs (NV), pigs with viremia <106 (V<106) 
and pigs with viremia ≥106 (V≥106) viral genome copy number / ml of serum. 
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Higher IL-8, TNF-α and IFN-γ levels were detected in the PCV2-vac group, testifying a more 
efficient immune responsiveness, especially when compared to the Ctrl-PMWS+ group.  
In Ctrl-PMWS+ pigs, lower IFN-γ at 19 weeks of age was associated with high IL-10 at                
19 weeks of age and low levels of pro-inflammatory cytokines at 22 weeks of age, namely     
IL-8 and TNF-α, a condition likely correlated with the onset of the disease.  
Contrarily, at 19 weeks of age, PCV2-vac and Ctrl pigs showed lower IL-10 expression, 
together with higher IFN-γ levels than the Ctrl-PMWS+ animals. At 22 weeks of age, 
vaccinated animals maintained higher levels of the pro-inflammatory cytokines. 
These evidences support that the outcome of PMWS could be associated with a reduction of 
the innate/pro-inflammatory response. Overall, the results show a different cytokine 
modulation in vaccinated and unvaccinated-infected pigs also developing PMWS. Vaccinated 
pigs coped with infection showing low or absent viremia burden, absence of PMWS disease 
and stronger inflammatory response and cellular IFN-γ-related reactivity. 
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Riassunto 
Il Circovirus suino di tipo 2 (PCV2) è stato identificato come il principale agente eziologico 
della sindrome da deperimento post-svezzamento del suino (PMWS), una delle patologie del 
suino maggiormente diffuse in tutto il mondo, comunemente indicata, insieme ad altre 
patologie legate all’infezione da PCV2, come facente parte delle malattie associate al 
circovirus suino (PCVD).  
La strategia più importante per controllare e prevenire le malattie associate a PCV2, oltre alle 
procedure di gestione e controllo delle coinfezioni, è la vaccinazione dei suinetti o delle scrofe 
e delle scrofette. Tre sono i vaccini commerciali oggi disponibili; anche se è stata dimostrata 
la loro efficacia nel ridurre la viremia e le lesioni presenti nei tessuti linfoidi indotte dal virus, 
i meccanismi attraverso i quali questi vaccini sono in grado di indurre un’immunità protettiva 
non sono ancora stati completamente chiariti. 
A parte lo sviluppo di una risposta immunitaria di tipo umorale generalmente caratterizzata 
dalla presenza di anticorpi totali e anticorpi virus neutralizzanti PCV2-specifici, i meccanismi 
che permettono all’immunità adattativa cellulo-mediata di controllare l’infezione data da 
PCV2 e le malattie ad essa associate non sono stati completamente compresi, specialmente in 
condizioni di campo. 
In questo lavoro di Tesi è stata valutata l’efficacia di un vaccino monodose verso PCV2, 
basato sulla proteina capsidica Cap del virus espressa in un sistema baculovirus, 
somministrato in due diversi allevamenti (allevamento 1 e 2) con anamnesi di malattia 
associata a circovirus suino di tipo 2 (PCVD). 
Sono stati considerati parametri quali morbilità, mortalità, incremento ponderale giornaliero, 
peso della carcassa, titolo di PCV2 nel siero e immunogenicità del vaccino in termini di 
anticorpi specifici verso PCV2, di frequenza di cellule secernenti IFN-γ PCV2-specifiche e di 
livelli d’espressione genica di importanti citochine pro-infiammatorie e immunitarie. Sono 
state inoltre effettuate analisi sierologiche verso potenziali coinfezioni sostenute da virus della 
sindrome riproduttiva e respiratoria del suino (PRRSV) e Mycoplasma hyopneumoniae                 
(M. hyo.).  
È stata condotta una prova di campo in doppio-cieco, randomizzata e con gruppo di controllo 
distribuendo 818 suineti in due gruppi di trattamento. All’inizio della prova (giorno dello 
svezzamento: 21±3 giorni di età), 408 suinetti (gruppo vaccinato) hanno ricevuto una dose di 
vaccino Porcilis PCV®, risospeso in adiuvante a base di tocoferolo (Diluvac Forte®), per via 
intramuscolare (2 ml). Gli animali controllo (410 suinetti) hanno ricevuto 2 ml di solo 
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adiuvante per via intramuscolare. L’aumento ponderale giornaliero (ADWG) è stato calcolato 
misurando il peso degli animali all’inizio della prova, a 12 e a 16 settimane di età. I pesi delle 
carcasse dei suini dell’allevamento 2 sono stati registrati al momento della macellazione             
(274 giorni di vita). Tutti gli animali morti (morti o abbattuti) sono stati sottoposti ad autopsia 
per essere classificati come animali affetti o non affetti da PMWS.  
In ciascun allevamento sono stati prelevati campioni di sangue per effettuare indagini 
sierologiche e della componente immunitaria cellulare. La risposte immunitarie umorali e 
cellulo-mediate dei suini sono state valutate rispettivamente mediante ELISA, per rilevare il 
titolo degli anticorpi PCV2-specifici nel siero, e tecnica ELISpot, per misurare la frequenza 
delle cellule secernenti IFN-γ PCV2-specifiche nelle PBMC.  
I risultati riportati nella presente Tesi suggeriscono che una singola dose di vaccino basato 
sulla proteina Cap di PCV2 sia efficace contro l’insorgenza delle PCVD e in particolare della 
PMWS.  
La vaccinazione ha ridotto il tasso di mortalità e morbilità, la viremia specifica per PCV2 e la 
carica virale, portando a un miglioramento delle performance produttive (es. ADWG:                     
70 g/giorno tra 12 e 26 settimane di età, quando si registra l’insorgenza di viremia e malattia 
ad essa associata) e del peso della carcassa alla macellazione (+4,5 kg). Questi effetti sono 
stati associati alla protezione dall’infezione e dal manifestarsi di sintomatologia clinica 
determinata dall’immunogenicità del vaccino, misurata come attivazione della risposta 
immunitaria umorale e cellulo-mediata. A questo proposito, la quantificazione mediante 
tecnica ELISA degli anticorpi PCV2-specifici ha dimostrato sieroconversione (fatta eccezione 
per i suini con titolo di anticorpi di derivazione materna >8 log2) e immunità protettiva di 
lunga durata in tutti i suini vaccinati.  
Inoltre, l’aumentata frequenza delle cellule secernenti IFN-γ PCV2-specifiche, quantificata 
mediante tecnica ELISpot durante il periodo post-vaccinazione, ha dimostrato la capacità di 
una singola dose di vaccino basato sulla proteina Cap di PCV2 di indurre una risposta 
immunitaria cellulo-mediata virus-specifica.  
Durante il periodo post-esposizione gli animali vaccinati hanno contrastato efficacemente e 
rapidamente la replicazione virale; l’immunità umorale e cellulo-mediata sono risultate infatti 
associate ad una bassa o assente viremia e segni clinici di minor gravità. 
Inoltre, al fine di ottenere informazioni più approfondite sui meccanismi di reattività 
immunitaria cellulare, sono stati valutati i profili d’espressione di importanti citochine                
pro-infiammatorie (IL-8, TNF-α, IL-1β) e immunitarie (IFN-γ, IL-10). La modulazione 
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dell’espressione citochinica e il corso della viremia sono state valutate in 10 animali vaccinati 
contro PCV2 e 20 animali non vaccinati dell’allevamento 1. Queste analisi sono state 
effettuate mediante PCR quantitativa Retro Trascizionale (RT-qPCR) prima dell'insorgenza 
della viremia associata a PCV2 (16 settimane di età) e a seguito dell'infezione da PCV2 e la 
comparsa di sintomatologia clinica da PMWS (19 e 22 settimane di età). 
La risposta citochinica è stata valutata tenendo in considerazione gli evidenti segni clinici 
relativi alla PMWS e al corso della viremia, suddividendo gli animali in tre gruppi: 1) suini 
vaccinati (PCV2-vac); 2) suini non vaccinati spontaneamente infettati/non affetti da PMWS 
(Ctrl); 3) suini non vaccinati spontaneamente infettati/affetti da PMWS (Ctrl-PMWS+). 
Inoltre, per determinare un’associazione tra l’espressione delle citochine e l’andamento della 
viremia, ciascuno dei gruppi sopracitati è stato analizzato dividendo gli animali in tre diversi 
sottogruppi definiti sulla base del titolo virale (numero di copie di genoma virale/ ml di siero): 
suini non viremici (NV), suini con viremia<106 (V<106) e suini con viremia ≥106 (V≥106). 
Gli alti livelli di IL-8, TNF-α e IFN-γ rilevati nel gruppo PCV2-vac indicano che questi 
animali hanno mostrato una responsività immunitaria più efficiente, specialmente se 
confrontati al gruppo di animali Ctrl-PMWS+. 
Nei suini Ctrl-PMWS+, rispetto agli altri gruppi sperimentali, sono stati osservati livelli più 
ridotti di IFN-γ a 19 settimane di età, associati a più elevati livelli di IL-10 a                             
19 settimane di età e ad una più ridotta espressione di citochine pro-infiammatorie a 22 
settimane di età, in particolare IL-8 e TNF-α, condizione probabilmente correlata 
all’insorgenza della malattia. Al contrario, a 19 settimane di età, i suini dei gruppi PCV2-vac 
e Ctrl hanno mostrato una più bassa espressione di IL-10 e maggiori livelli di IFN-γ rispetto 
agli animali Ctrl-PMWS+. A 22 settimane di età gli animali vaccinati hanno mantenuto livelli 
di citochine pro-infiammatorie più elevati. 
Questi dati supportano l’ipotesi che l'esito della PMWS potrebbe essere associato ad una 
riduzione della risposta immunitaria innata/pro-infiammatoria. Complessivamnete, i risultati 
mostrano una diversa modulazione citochinica tra i suini vaccinati e non vaccinati infetti da 
PCV2 che sviluppano PMWS. I suini vaccinati combattono l'infezione mostrando ridotta o 
assente viremia, assenza di PMWS e una risposta infiammatoria e reattività cellulare associata 
all’IFN-γ più intense. 
 VII 
Table of Contents 
 
CHAPTER 1. INTRODUCTION .....................................................................................................1 
 
1.1 Porcine circovirus type 2 (PCV2) ...........................................................................................2 
 
1.1.1 PCV2 history....................................................................................................2 
 
1.1.2 Taxonomy.........................................................................................................3 
 
1.1.3 Genotypes.........................................................................................................3 
 
1.1.4 Molecular characteristics..................................................................................4 
 
1.1.5 PCV2-associated diseases ................................................................................7 
 
1.2 Postweaning multisystemic wasting syndrome (PMWS)....................................................10 
 
1.2.1 Epidemiology .................................................................................................10 
 
1.2.2 Clinical features..............................................................................................11 
 
1.2.3 Diagnosis ........................................................................................................12 
 
1.2.4 Pathogenesis ...................................................................................................13 
 
1.2.5 Intervention strategies ....................................................................................15 
 
1.2.6 Vaccine development and vaccination...........................................................16 
 
1.2.7 Effectiveness of vaccination...........................................................................17 
 
1.3. PCV2 and the immune system .............................................................................................19 
 
1.3.1 Interaction between PCV2 and immune cells ................................................19 
 
1.3.2 Humoral response...........................................................................................22 
 
1.3.3 Cell-mediated immune responses...................................................................23 
 
1.3.4 PCV2 modulation of cytokine profiles...........................................................24 
 
CHAPTER 2. OBJECTIVES OF THE RESEARCH...................................................................26 
 
CHAPTER 3. EXPERIMENTAL STUDY UNDER FIELD CONDITIONS.............................30 
 
3.1. Materials and methods..........................................................................................................31 
 
3.2. Results ....................................................................................................................................41 
 
CHAPTER 4. DISCUSSION AND CONCLUSIONS...................................................................67 
 
CHAPTER 5. REFERENCES ........................................................................................................77 
 
CHAPTER 6. RESEARCH ACTIVITIES AND PUBLICATIONS ...........................................92 
 VIII 
List of abbreviations 
ADV  Aujeszky’s disease virus  
ADWG average daily weight gain  
AM   alveolar macrophages  
BMDC  bone-marrow derived dendritic cells  
Ctrl  controls (unvaccinated spontaneously infected/non-PMWS-affected pigs) 
Ctrl-PMWS+  controls-PMWS+ (unvaccinated spontaneously infected/PMWS-affected pigs) 
DC  dendritic cells 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
HI  haemoagglutination inhibition 
ICTV  International Committee for the Taxonomy of Viruses 
IFN   interferon  
Ig  immunoglobulin  
IL  interleukin 
MDA  maternally derived antibodies 
M. hyo Mycoplasma hyopneumoniae 
MdM    monocyte-derived macrophages  
MOI  multiplicity of infection 
NA  neutralising antibodies 
ODN  oligodeoxynucleotides 
PCV  porcine circovirus 
PCV1  porcine circovirus type 1 
PCV2  porcine circovirus type 2  
PCVAD porcine circovirus associated diseases 
PCVD  porcine circovirus diseases 
PMWS postweaning multisystemic wasting syndrome 
PPV  porcine parvovirus 
PCV2-vac PCV2-vaccinated pigs 
PRRSV porcine reproductive and respiratory syndrome virus 
RT-qPCR reverse transcription-quantitative PCR (polimersase chain reaction)  
SC  secreting cells  
SIV  swine influenza virus 
 
  
CHAPTER 1. 
 
 
 
 
 
 
INTRODUCTION 
 
Chapter 1                                                                                                                             Introduction 
2 
1.1 Porcine circovirus type 2 (PCV2)  
 
1.1.1 PCV2 history  
Porcine circovirus (PCV) was first detected in 1974 as a virus morphologically similar to a 
picornavirus, contaminating the porcine kidney cell line PK-15 (ATTC-CCL33)                        
(Tischer et al., 1974). This contaminant agent was subsequently demonstrated to be a circular 
single-stranded DNA (ssDNA) virus that was accordingly named porcine circovirus (PCV) 
(Tischer et al., 1982). Since the virus induced an antibody response but no disease in the pig 
population, it was defined as non-pathogenic (Tischer et al., 1986; Dulac and Afshar, 1989; 
Allan et al., 1994). 
 
Postweaning multisystemic wasting syndrome (PMWS) is a multifactorial disease that was 
first reported in North America in 1991 (Clark, 1997; Harding, 1997); since then, this disease 
has affected the swine industry worldwide. The clinical signs of this syndrome include weight 
loss, severe growth retardation and death in weaned piglets; PMWS is also characterized by a 
multiorgan disease including lymphadenopathy, respiratory dysfunction, hepatitis, 
splenomegaly and gastric ulcers (Clark, 1997; Harding, 1997), lymphocyte depletion, 
monocytic infiltration in lymphoid tissues and high amounts of viruses in these lesions 
(Segalés et al. 2002).  
After the isolation of a PCV-like agent from tissues of PMWS-affected pigs, both in                 
North America and Europe (Allan et al., 1998b; Ellis et al., 1998), the non-pathogenic PK-15 
cell culture-derived virus and the circovirus isolated from PMWS-affected pigs were 
compared. Nucleotide sequence analyses revealed significant genetic differences between 
viruses (Allan et al., 1998a), less than 80% of sequence identity (Meehan et al., 1998); 
because of that they were divided into two types: the non pathogenic PCV type 1 (PCV1) and 
the virus associated with clinical disease, that is PCV type 2 (PCV2) (Hamel et al., 1998; 
Meehan et al., 1998).  
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1.1.2 Taxonomy 
Both PCV1 and PCV2 belong to the Circoviridae family (Todd et al. 2005; Opriessnig et al. 
2007) that is composed of icosahedrical, small, non-enveloped ssDNA viruses infecting 
vertebrates (Lukert et al., 1995). Viruses within the Circoviridae family, based of their 
morphology and genomic organization, are divided in two genera: Circovirus and Gyrovirus 
(Todd et al. 2005; Opriessnig et al. 2007).  
Circovirus genus includes Porcine circovirus type 1 and type 2 and, according to the 
International Committee for the Taxonomy of Viruses (ICTV), other known avian viruses 
such as Beak and feather disease virus (Ritchie et al., 1989), Canary circovirus (Phenix et al., 
2001), Duck circovirus (Hattermann et al., 2003), Finch circovirus (Shivaprasad et al., 2004), 
Goose circovirus (Todd et al., 2001), Gull circovirus (Smyth et al., 2006), Pigeon circovirus 
(Woods et al., 1993), Starling circovirus (Johne et al., 2006) and Swan circovirus                     
(Halami et al., 2008).  
The genus Gyrovirus, that differs from circovirus for its negative sense genome and its large 
virions (Gelderblom et al., 1989; Gillespie et al., 2009), contains only Chicken anaemia virus 
(CAV) (Todd et al., 2005; Opriessnig et al., 2007).  
 
 
1.1.3 Genotypes 
Several phylogenetic analyses have demonstrated that PCV2 isolates from different 
geographical origins can be divided into 2 distinctive genogroups (Larochelle et al., 2002; 
Mankertz et al., 2000; Olvera et al., 2007). In some studies a stronger association of certain 
PCV2 genogroups with the PCVD onset (Grau- Roma et al., 2008; Timmusk et al., 2008) has 
been described whereas other reports have stated that there is no direct relationship between 
the development of PMWS and the infection by a specific genogroup of PCV2                         
(Allan et al., 2007; Olvera et al., 2007). The difficulty to identify pathogenic differences 
between genotypes has been recently attributed to the presence of a conserved decoy epitope 
in the C-terminal region of the PCV2 capsid protein (Trible and Rowland, 2011). 
The two phylogenetic groups, depending on the author, have been commonly referred as 
PCV2a and PCV2b in North America and PCV2 group 1 (included in the PCVb group) and 
PCV2 group 2 (included in the PCVa group) in Europe. In addition, some North American 
laboratories, based on predicted restriction fragment length polymorphism (RFLP) patterns, 
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grouped the virus into two RFLP patterns designated as 422 and 321. Isolates with the RFLP 
pattern 422 typically cluster into PCV2a (PCV2 group 2), whereas isolates with a 321 RFLP 
pattern can be either PCV2a (PCV2 group 2) or PCV2b (PCV2 group 1) (Olvera et al., 2007; 
Opriessnig T. et al., 2007).  
Nowadays the North American nomenclature is officially accepted and the two clusters are 
designated as PCV2a and PCV2b (Gagnon et al., 2007; Segalés et al., 2008); PCV2a contains 
a genome of 1.767 nucleotides (nt) and can be divided into 3 clusters (1A–1C), while PCV2b 
is characterised by a 1.768 nt genome and can be divided into 5 clusters (2A–2E)                       
(Olvera et al., 2007; Gillespie et al., 2009). The existence of discrete antigenic differences 
between different PCV2 genetic clusters has been described in a recent study that performed 
epitopes’ competition analysis using a panel of universal and cluster-specific mAbs                        
(Saha et al., 2011). 
Several epidemiological studies worldwide have reported that PCV2b is becoming 
predominant in many countries, underling a genotype switch of virus from PCV2a 
(circulating with prevalence in the 1990’s) to this major group (Trible and Rowland, 2011). A 
new PCV2 genogroup, PCV2c has been recently detected in Denmark in archived serum 
samples from non-clinical pigs collected in 1980, 1987 and 1990; furthermore, it has been 
demonstrated that this genogroup is more closely related to PCV2b (95%) than PCV2a (91- 
93.6%) as sequence homology (Dupont et al. 2008; Opriessing et al. 2010).  
 
 
1.1.4 Molecular characteristics  
Porcine circoviruses (PCVs) are the smallest viruses infecting mammalian cells, being 
characterised by an icosahedral, non-enveloped virion particle of 17±1.3 nm of diameter 
(Tischer et al., 1982) that contains a covalently closed circular ssDNA genome with a size of 
1759 bp and 1768 bp for PCV1 and PCV2 respectively (Meehan et al., 1998). PCVs, as the 
other Circoviruses, replicate via rolling circle replication (RCR) so, after the infection of the 
cells, their ssDNA is converted into a intermediate dsDNA, called replicative form (RT). 
During this phase of the viral life cycle, the genome has an ambisense organization and genes 
encoded by both the positive and negative strands (Cheung 2006; Meehan et al., 1997) 
(Fig.1). 
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Figure 1. PCV2 and PCV1 genomes (adapted from Gillespie J. et al., 2009)  
 
 
This arrangement creates two intergenic regions, a shorter one between the 3’-ends of the     
Rep and Cap gene and a larger one between their 5’-ends, the latter comprising the origin of 
viral genome replication (Finsterbusch T. and Mankertz A., 2009). The origin of replication 
(OR) is characterized by a putative stem–loop structure with a nonamer in its apex and 
hexamer motifs, contiguous to the stem–loop, which serve as binding site for the replicases 
(Mankertz et al., 1997; Finsterbusch T. and Mankertz A., 2009) (Fig. 2).  
PCV2 replication starts when Rep protein binds these hexamer repeats (Mankertz et al., 2004) 
and, since PCV2 is dependent on cellular DNA polymerases, meanwhile the Rep proteins 
nick and join the nucleotide segments at the initiation and termination of the cycle, the 
cellular polymerase synthesizes DNA (Cheung 2006; Steinfeldt et al., 2006). 
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Figure 2. A linear representation of the PCV genome (upper part); the two major ORF, rep and cap, 
three motifs conserved in RCR enzymes (I–III), a dNTP-binding domain (P) within the rep gene and 
the ORF3 (grey boxes) are indicated. The lower part shows a comparison of the two origin regions of 
PCV1 and PCV2; the hexamer repeats 1–4 (open boxes), the conserved nonamer sequence within the 
single-stranded loop of the hairpin (grey box) and the nicking site (arrow) are indicated              
(Finsterbusch T. and Mankertz A., 2009). 
 
 
PCV2 genome contains several potential open reading frames (ORFs) larger than 200 nt, 
however only three of them have been demonstrated to be functionally expressed:                      
ORF1 (Rep), ORF2 (Cap) and ORF3 (Hamel et al., 1998; Segalés et al., 2005; Liu et al., 
2005). ORF1 is located on the positive strand, clockwise oriented and encodes for the viral 
replication proteins Rep and Rep’ which are 314 and 178 amino acids (aa) in length, 
respectively (Mankertz et al., 1998; Cheung, 2003b). ORF2 is situated on the negative strand, 
counterclockwise oriented, and encodes for the capsid protein Cap which is the major 
structural protein and the main antigenic determinant of the virus (Mankertz et al., 2000; 
Nawagitgul et al., 2000). ORF3 is completely overlapped with the ORF1 gene, located in the 
negative strand and counterclockwise oriented, it encodes for a protein that has been 
characterized as an inducer of apoptosis (Liu et al., 2005; Liu et al., 2007). Several recent 
studies have shown that the ORF3 protein might play a role in viral replication and induction 
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of immunosuppression (Karuppannan et al., 2009); indeed it has been proved, both in 
BALB/c mice (Liu J. et al., 2006) and in specific-pathogen-free (SPF) piglets, that the knock-
out of ORF3 reduces PCV2 pathogenicity (Karuppannan, A. K., 2009). The non pathogenic 
PCV1 also has a third open reading frame but its function has still to be characterised 
(Chaiyakul M. et al., 2010). 
 
 
1.1.5 PCV2-associated diseases 
All the recognized syndromes associated with PCV2 infection can be nowadays designated by 
two similar terms: PCVD (porcine circovirus diseases), proposed in 2002 by Allan and                 
co-workers and still predominantly used in Europe, and PCVAD (porcine circovirus 
associated diseases), introduced by the American Association of Swine Veterinarians 
(AASV) in 2006 and used mainly in North America. At present there is still no consensus 
with regard to the disease nomenclature and both acronyms are accepted.  
PCV2 is the primary causative agent of the syndromes included in PCVD but many other 
common pathogens are involved in their onset; the different forms can be accomplished by 
observation of characteristic lesions in the intestines, lungs, and lymphoid tissue                 
(Opriessnig et al., 2007).  
PCV2 has been associated with subclinical diseases or other clinical manifestations such as 
postweaning multisystemic wasting syndrome (PMWS), PCV2-Associated Enteritis, PCV2-
Associated Pneumonia, PCV2-Associated Reproductive Failure, Porcine Dermatitis and 
Nephropathy Syndrome (PDNS) and PCV2-Associated Neuropathy (Gillespie et al., 2009).  
The syndromes associated with PCV2, besides PMWS, are the following: 
 
- Subclinical infections characterised by the absence of evidence of clinical disease although 
PCV2 is present. In vivo study on PCV2-inoculated pigs have shown that PCV2 lesions can 
be limited to 1 or 2 lymph nodes without causing any apparent clinical problems              
(Opriessnig et al., 2004; Opriessnig et al., 2006a); cases of necrotising lymphadenitis 
(Opriessnig et al., 2006a; Kim et al., 2005) or decrease in vaccine efficacy have also been 
reported in healthy PCV2-infected pigs (Opriessnig et al., 2006b).  
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- PCV2-Associated Enteritis affects piglets from 8 to 16 weeks of age inducing increased 
mortality, diarrhea and severe growth retardation: this syndrome is similar in clinical signs to 
ileitis associated with Lawsonia intracellularis infection but an histopathological study can 
distinguish between the two diseases; animals affected by PCV2-Associated Enteritis are 
indeed characterised at necroscopy by an enlargement of mesenteric lymph nodes, thickening 
of intestinal mucosa (Jensen et al., 2006), distinctive PCV2 lesions in Peyer’s patches but not 
in other lymph nodes and granulomatous entheritis detectable by means of microscopical 
analysis. 
 
- PCV2-Associated Pneumonia occurs in pigs from 8 to 26 weeks of age and its 
symptomatology includes reduced feed efficiency and growth rate, anorexia, fever, cough, 
and dyspnea (Gillespie et al., 2009); histopathological studies on diseased pigs show 
lymphohistiocytic to granulomatous bronchointerstitial pneumonia with necrotizing and 
ulcerative bronchiolitis and bronchiolar fibrosis characterised by abundant PCV2 antigen in 
the lesions. This evidence suggest that PCV2 may play a role in the Porcine Respiratory 
Disease Complex (PRDC) in which also Porcine Reproductive and Respiratory Syndrome 
Virus (PRRSV) are involved (Sorden, 1999; Sorden et al., 2000; Gillespie et al., 2009). 
 
- PCV2-Associated Reproductive Failure damage herds of gilt startups or new populations 
(Mikami et al., 2005) inducing clinical manifestations as increased abortion, still births, foetal 
mummies, and pre-weaning mortalities; a non-suppurative to necrotizing or fibrosing 
myocarditis has been also found in histopathological lesions of stillborn and neonatal pigs 
(Mikami et al., 2005; Opriessnig et al., 2007). It has been proved that the time of infection 
determines the clinical course of the disease: several studies have demonstrated that fetuses 
experimentally intrauterine infected in an earlier phase of gestation (57 weeks of gestation) 
present higher viral load and lesions as edema, enlarged liver and congestion, than those 
infected in a later phase (75 and 92 days of gestation) (Sanchez et al., 2001); it has been also 
shown that late term infections (86, 92, and 93 days of gestation) can cause an increase in 
reproductive abnormalities (Johnson et al., 2002; Gillespie et al., 2009). 
 
- Porcine Dermatitis and Nephropathy Syndrome (PDNS) was first described in the 
United Kingdom in 1993 (Smith et al., 1993) and was associated with PCV2 only later, in 
2000 (Rossel et al., 2000). Many pathogens including PRRSV and bacteria such as 
Chapter 1                                                                                                                             Introduction 
9 
Pasteurella multocida, Streptococcus suis type 1 and 2, among others, have been implicated 
in the etiology of disease (Lainson et al., 2002; Thomson et al., 2002). PDNS is not always 
associated with PCV2, in several studies it was indeed experimentally reproduced with 
PRRSV and TTV in PCV2-free pigs (Krakowka et al., 2008). 
This disease mostly affects growing pigs but can also occur in recently weaned and feeder 
pigs from 1.5 to 4 months of age (Smith et al., 1993; Thibault et al., 1998); PDNS is clinically 
characterized by an acute onset of multifocal and well circumscribed skin lesions                      
(raised purple progressing to multifocal raised red scabs with black centers most prominent on 
the rear legs), fever, and lethargy and is often fatal within 3 days of development                       
(Done et al., 2001; Duran et al., 1997; Chae, 2005). Macroscopically, the kidney appears 
enlarged and having pale cortex with multiple red circular haemorrhagic cortical foci (Ramos-
Vara et al., 1997). Microscopically, the most significant lesion is the severe, fibrinoid, 
necrotizing vasculitis in the dermis, subcutis, lymph nodes, stomach, spleen, liver and kidney 
which can be associated with dermal and epidermal necrosis and necrotizing and fibrinous 
glomerulonephritis.  
 
- PCV2-Associated Neuropathy causes in pigs congenital tremors and a nonsuppurative 
menigoencaphalitis associated with demyelination of the brain and spinal cord                        
(Larochelle et al., 2002; Pensaert et al., 2004; Correa et al., 2007). PCV2 infection has also 
been associated with cerebellar lymphohistiocytic vasculitis or with lymphohistiocytic 
meningitis (Correa et al., 2007) but even today the role played by this virus in this kind of 
diseases  has still to be clarified. 
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1.2 Postweaning multisystemic wasting syndrome (PMWS) 
The most significant manifestation of PCVAD is the postweaning multisystemic wasting 
syndrome (PMWS). Since the 1990s, porcine circovirus type 2 (PCV2) has been considered 
the causative agent of this disease, even if the majority of infections caused by PCV2 are 
sub-clinical, and only a small proportion of PCV2-infected pigs develops the clinical form of 
disease. PMWS is considered a multifactorial disease and the fully clinical expression of this 
syndrome is indeed due to the co-presence of PCV2 and pathogens such as porcine 
reproductive and respiratory syndrome virus (PRRSV), swine influenza virus (SIV), porcine 
parvovirus (PPV), Haemophilus parasuis, Actinobacillus pleuropneumoniae,              
Streptococcus suis and Mycoplasma hyopneumoniae (Chae, 2004). 
 
 
1.2.1 Epidemiology 
PMWS was described for the first time in a Canadian high-health-status herd in 1991 and was 
later recognized worldwide (Allan and Ellis, 2000) being associated with major losses in 
Europe (Harding et al., 2000; Opriessing et al., 2008). In 1996, both in British and French 
farms, there were cases of wasting and high losses in growing pigs (Madec et al., 2004)                
and PCV2 was isolated from the animals and the disease was later defined as PMWS.  
Cases of PMWS were retrospectively identified in archived serum and tissues samples from 
1962 in Germany (Jacobsen et al., 2009), 1969 in Belgium (Sanchez et al., 2001a), 1970                
in the United Kingdom (Grierson et al., 2004), 1973 in Ireland (Walker et al., 2000) and 1985 
in Canada and Spain (Magar et al., 2000; Rodríguez-Arrioja et al., 2003).  
During the following decade, PMWS spread over the world becoming a considerable 
economic problem in many pig-producing countries. In fact, PCV2 infection is so widespread 
today that it is almost impossible to find seronegative farms in epidemiology studies                   
(Grau-Roma et al., 2009). PMWS morbidity is associated with the development of clinical 
manifestations of disease and ranges between 4% and 30%, being (although) up to 60% in 
some herds (Segalés and Domingo, 2002). PMWS prevalence generally ranges from 4% to 
30% and mortality ranges from 4% to 20%, but can reach 50% (Allan and Ellis 2000;  
Harding and Clark, 1997; Segalés and Domingo, 2002).  
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1.2.2 Clinical features  
PCV2 infection can occur during the whole pig productive life, but PMWS usually affects 
animals from 8 to 16 weeks of age (Sibila et al., 2004; Grau-Roma et al., 2009).  
However, PMWS has been shown to occur at different ages in the United States                         
(from 7 to16 weeks of age) and Europe (from 5 to 12 weeks of age) (Allan and Ellis 2000; 
Segalés and Domingo, 2002) due to different management and vaccination practices. 
Clinical signs of this disease include wasting with progressive weight loss (Fig. 3), lethargy, 
dark-colored diarrhea, and paleness or jaundice that may occur at a different degree                
(Segalés et al., 2005; Allan and Ellis 2000; Gillespie J. et al., 2009). The earliest symptoms 
are weight loss, ill-thrift, pale skin, and rough hair; dyspnea, tachypnea, anemia, diarrhea, and 
jaundice generally appear in the latest phases of the disease, in some cases coming with 
coughing and gastric ulceration (Opriessnig et al., 2007; Gillespie J. et al., 2009). 
Gross lesions of PMWS commonly include pale and enlarged lymph nodes                        
(superficial inguinal, submandibular, mesenteric and mediastininal), mottled and firm lungs 
that fail to collapse (Allan and Ellis, 2000) and, in chronic cases, kidneys with white streaks 
or spots (Rosell et al., 1999). The histopathological analysis of PMWS lesions displays a 
generalised lymphoadenopathy with infiltration of histiocytic cells and multinucleated giant 
cells and characterised by pronounced depletion of lymphocytes. These findings are unique 
and allow to distinguish this syndrome from other wasting manifestations.  
 
 
Figure 3. Pigs suffering from PMWS (A) compared to a healthy pig of the same age (B)                
(Opriessnig et al., 2007). 
A 
B 
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The lymphatic system can be involved at different levels by the disease. Based on that, a 
scoring system has been defined to evaluate the severity of the disease. This estimation 
system allow to assign scores from 0 to 9 ranking the severity of lesions, the amount of PCV2 
antigen and the distribution of lesions in seven indicative lymphoid tissues such as the 
tracheobronchial lymph nodes, the mesenteric lymph nodes, the mediastinal lymph nodes, the 
superficial inguinal lymph nodes, the external iliac lymph nodes, the tonsils, and the spleen 
(Opriessnig at al., 2004; Gillespie et al., 2009). 
In case of PMWS the immune system of pigs can be strongly compromised and this can 
increase the probability to be subjected to secondary infections (Segalés et al., 2005). 
 
 
1.2.3 Diagnosis  
PCV2 induces several clinical signs that are also shared by other pig diseases; for this reason 
a diagnosis of a specific syndrome is not easy to define. The presence of PCV2 genome in 
serum and the observation of a diseased status of pigs is not enough to define a PCVD case.  
It has been established that to make a diagnosis of PCVD, in addition to clinical signs, PCV2 
antigen has to be necessarily found in more than one lymphoid tissue, or one lymphoid tissue 
and one other organ such as the lungs, liver, kidney or intestine, or in two organs                    
(Gillespie et al., 2009). 
More specifically, to categorise PMWS cases, Segalés and co-workers suggested in 2005             
the following criteria: 
1) clinical signs compatible with PMWS (growth retardation and wasting); 
2) moderate to severe histopathological lesions characterized by lymphocyte depletion 
together with granulomatous inflammation; 
3) moderate to high amount of PCV2 genome/antigen within lesions.  
 
Tests such as polymerase chain reaction, in situ hybridization (ISH) and 
immunohistochemistry (IHC) are considered the optimal techniques to detect PCV2 antigen 
or nucleic acid and make a diagnosis of PMWS (Opriessnig et al., 2007). Serological tests 
such as IPMA (immunoperoxidase monolayer assay) or SN (seroneutralisation) are useful to 
identify an infectious state but not enough to substitute histopathological evaluations and PCR 
analysis (Allan et al., 1998b; Grierson et al., 2004; Allan et al., 2000; Gillespie et al., 2009). 
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Seropositivity to PCV2 can be found in many clinically healthy pigs and the status of 
subclinical infection is commonly set when low amounts of PCV2 are detected in blood 
and/or tissues, associated with no or minimal lesions. The cut-off generally considered to 
distinguish between PMWS-diseased pigs and sub-clinically infected pigs is 107 PCV2 DNA 
copies/ml of serum (Opriessnig et al., 2007). 
Currently, there is no field test for the diagnosis of PMWS, but to identify and manage its 
outbreaks within a herd it is important to determine whether the disease is a significant or a 
sporadic problem. It has been defined that there is an important herd problem if the following 
conditions are observed (Segales J., 2006; Gillespie et al., 2009): 
1) significant increased postweaning mortality that is equal or higher than the mean 
historical mortality plus 1.66 times the standard deviation. If historical data are not 
available, a herd problem can be described when the postweaning mortality exceeds 
the national or regional level by 50% or more; 
2) confirmation of PMWS in individual cases.  
 
 
1.2.4 Pathogenesis 
In case of PCV2 infection there are significant differences between sub-clinical and               
PMWS-affected pigs; current evidence support a central role for immunodepression in the 
pathogenesis of PMWS.  
In pigs that develop PMWS, the highest amount of PCV2 is found in the cytoplasm of 
monocyte and machrophage lineage cells (Rosell et al., 1999; Sanchez et al., 2004).  
The virus can infect these cells without an active replication for a long period of time                
(Gilpin et al., 2003; Vincent et al., 2003). The capability of PCV2 to induce functional 
impairment of in vitro cultured dendritic cells (DC) has been also described (Vincent et al., 
2005); this underlines the ability of the virus to interfere with innate and virus-specific 
immune responses.  
It has been displayed that PCV2 is not able to encode for its own polymerase and its 
replication depends on host’s nuclear polymerases (Tischer et al., 1987). For this reason it is 
possible to identify cells that support replication of PCV2 by evaluating the presence of Rep, 
the PCV2 replication associated protein, in the nucleus of the cell (Rovira et al., 2002). Earlier 
studies have demonstrated the presence of nuclear PCV2 in epithelial cells of PMWS-affected 
pigs, proposing these cells as candidate for primary PCV2 infection (Rossel et al., 1999).  
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Studies on experimentally PCV2-inoculated pigs have proven viral replication in lymphocytes 
from PBMC and bronchial lymph nodes by measuring Cap mRNA levels in the cells                    
(Yu et al., 2007a). The subpopulations of leukocytes that support PCV2 replication are 
prevalently circulating T cells, both CD4+ and CD8+, and in a lower proportion                                
B lymphocytes; PBMC-derived monocytes do not seem to sustain viral replication                        
(Yu et al., 2007b; Lefebvre et al., 2008b; Lin et al., 2008). 
PMWS is characterised by lymphocyte and follicular dendritic cell depletion from follicular 
regions, together with increased numbers of histiocytic cells (Chianini et al., 2003).  
It is still unknown whether the lymphocyte depletion is due to reduced production in the bone 
marrow, reduced proliferation in secondary lymphoid tissues, or increased loss of 
lymphocytes in the bone marrow, peripheral blood, or secondary lymphoid tissues via                
virus-induced necrosis or apoptosis (Opriessnig et al., 2007). A reduction of B and T 
lymphocytes, especially CD8+ cells, has been also reported in blood circulation; at the same 
time, an increased number of circulating neutrophils and monocytes determine a reversal of 
the normal ratio of lymphocytes/neutrophils (Nielsen et al., 2003; Segales et al., 2001). 
Infection studies have not clarified yet this phenomenon. 
An experimental PCV2 infection study showed that at 7 days post-PCV2 infection the 
lymphocyte depletion has already started, whereas maximal depletion of both B and T cell 
subsets, followed by a huge or total loss of NK cells, occurs later, at 21 days post-infection 
(Nielsen et al., 2003).   
Humoral immunity seems to play a very important role in controlling and resolving viremia 
(Fort et al., 2007; Opriessnig et al., 2008b). In sub-clinical animals, an efficient humoral 
response is frequently associated with long-lasting viremia, low concentration of virus at 
lymphoid tissue, and no significant changes in the status of the immune system                          
(Allan et al., 1999a; Resendes et al., 2004a). On the contrary, weak humoral responses can be 
related to increased viral replication, resulting in the severe lymphoid lesions and 
immunosuppressive status characteristic of PMWS (Bolin et al., 2001). 
 
Several experimental and field studies supported the multifactorial nature of PMWS and 
highlighted that not all pigs that are infected by PCV2 develop clinical PCVAD.  
The outcome of this syndrome can be influenced by several factors that can be grouped in 
four main areas: virus, host, coinfections, and immune modulation (Opriessnig et al., 2007). 
The accurate mechanism by which these factors cooperate determining the onset of the 
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disease in PCV2-infected pigs are not completely been elucidated yet. A schematic diagram 
involving factors influencing the onset of PMWS and PCV2 infection progression/outcome is 
shown in Figure 4. 
 
 
 
Figure 4. Scheme of the current understanding of the progression of porcine circovirus type 2 (PCV2) 
infection and clinical outcome (Opriessnig et al., 2007).  
 
 
 
1.2.5 Intervention strategies 
Since the first economically significant appearance of PMWS in the 1990s, control measures 
have been focused on the control of risk factors involved in the progression of the disease, but 
have been accomplished with several problems mostly related to the lack of knowledge of the 
full aetiology and epidemiology of the disease and the absence of commercial vaccines.  
The first strategy to control PMWS by adjustments of housing and management routines in 
affected farms were proposed by Madec and co-workers in 2001; they elaborated a 20-point 
plan of recommendations essentially focused to reduce overall stress and improve hygiene 
and infection status within the herd. Due to difficulties in application on large commercial 
units, the Madec’s principles have been later refined into four rules: 1) limiting pig-pig 
contact, 2) reduction of physiological stress, 3) good hygiene conditions improving 
disinfection and cleaning procedures, and 4) good nutrition (Muirhead, 2002).  
5-30% 
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The implementation of Madec’s plan as a guideline for the control of postweaning mortality 
in PMWS affected farms proved to be efficacious in reducing the PMWS-associated losses 
(Allan and McNeilly, 2006; Segalés et al., 2005). 
 
 
1.2.6 Vaccine development and vaccination 
Vaccination against PCV2 represents an important strategy to control PMWS in pig herds. 
For this reason there is active interest in the development of vaccines able to prevent or limit 
the PCV2-associated diseases. Nowadays, several commercial products are used in the herds 
and all of them are based on PCV2a genotypes that have been demonstrated to provide                  
cross-protection also to PCV2b (Fort et al., 2008, 2009; Segalés et al., 2009).  
Nowadays, three commercially vaccines are available against PCV2: 
• CIRCOVAC
® 
(Merial) was the first vaccine on the market; it has been extensively 
used in Europe but it has been also available in Canada. It is an inactivated PCV2,            
oil-adjuvanted vaccine for use in sows and gilts 2-4 weeks prior to farrowing 
(Charreyre et al., 2005; Gillespie et al., 2009) that is given as two injections                       
IM (intramuscular administration) 3-4 weeks apart and completed at least 2 weeks 
before breeding and once at each subsequent gestation (Opriessnig et al., 2007).  
The active immunisation on these breeding-aged animals is used to induce passive 
immunisation to the offspring by means of colostrum transfer.  
 
The other two commercial products use different approaches for establishing protective 
immunity against PCV2. They are recombinant vaccines designed for use in growing pigs,              
at about 3-4 weeks of age.  
 
• Ingelvac CircoFLEX
®
 is a capsid-based subunit vaccine based on the product of the 
ORF2 expressed in a baculovirus system; it is administered as a single dose IM in 
piglets from 2 weeks of age. The immunity of the treated animals starts about 2 weeks 
after vaccination remaining protective at least for further 17 weeks. A significant 
decrease in mortality in vaccinated pigs compared to unvaccinated pigs was reported 
on 4 different Canadian finishing sites (Desrosier et al., 2007; Gillespie et al., 2009). 
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• The vaccine from Intervet/Schering-Plough/Merck is also a capsid-based subunit 
vaccine expressed in a baculovirus, it is designated as Porcilis PCV
®
in Europe and 
Asia and Circumvent PCV
 ®
 in the United States and Canada (Gillespie et al., 2009).  
 
Porcilis PCV 
®
 can be administered to 3-day-old and older piglets, following a double 
dose IM protocol (at 3-5 days and 3 weeks of age) or given as a single dose IM at                     
3 weeks of age; Circumvent
®
 is given to 3-week-old and older piglets and is 
administered as a single dose at 3 weeks of age. Both of them induce protective 
immunity that remains active from 2 to 22 weeks after vaccination; studies including 
35,000 pigs on 21 different farms showed that mortality of vaccinated pigs is reduced 
by 77.5% when compared to unvaccinated pigs (Grau et al., 2007; Gillespie et al., 
2009). 
 
 
1.2.7 Effectiveness of vaccination 
The effectiveness of the vaccines available against PCV2 has been widely evaluated in several 
studies. Due to the poor clinical manifestation in piglets infected by PCV2 only, some studies 
have also evaluated the responses in animals co-infected by two or three porcine pathogens. 
Experimental co-infection try to reproduce herd field conditions in which numerous 
pathogens, more frequently PRRSV and Mycoplasma Hyopneumoniae, contribute to PCVD 
outbreak (Beach and Meng, 2011). In this regard it has been found that the presence of 
PRRSV can increase the severity of PCV2-related clinical signs, inducing a wide spread of 
the virus by oronasal and faecal excretions (Allan et al., 2000; Rovira et al., 2002;                         
Sinha et al., 2011). Contrarily, a large number of vaccines against PCV2 have demonstrated to 
induce neutalising antibody (NA) secretion, reduced viral load and lymphoid lesions in cases 
of PCV2 infection but also in the presence of SIV (swine influenza virus) or PRRSV  
(Opriessnig et al., 2009) coinfections.  
The vaccination of boars by using Suvaxyn PCV2 one dose, followed by infection with PCV2 
or Mycoplasma, seems to prevent serious clinical manifestation, reduce viral titres in the 
blood and virus excretion by faeces and semen with respect to an unvaccinated control group 
(Opriessnig et al., 2011). Boars vaccination does not alter semen characteristics and is proved 
to be a good practice to reduce vertical PCV2 transmission. 
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In addition, sow and gilt vaccination has been reported to increase the number of live born 
pigs and the number of pigs per sow per year, reducing the number of mummies per sow 
(Thacker et al., 2008). It is relevant to highlight that the vaccination of sows is not able to 
completely eliminate viral transmission by colostrum or prevent intrauterine infection but is 
however important to increase productive parameters of the herds (Beach and Meng, 2011).  
 
Several studies have demonstrated the efficacy of PCV2 vaccination; in a infection study, 
vaccine treatment of piglets from a PRDC group reduced the mean viral titre from 83% to 
55% and its duration overtime, improving average daily weight gain (ADWG) (Fachinger et 
al., 2008). In another study, vaccination of piglets from a PMWS/PCVD farm showed a             
50% reduction of mortality and a 9.3 % increase of ADWG (Horlen et al., 2008).  
The efficacy of a subunit vaccine containing PCV2 capsid protein has been also proven after 
experimental infection with four different PCV2 isolates of the two genotypes (PCV2a and 
PCV2b) (Fort et al., 2008). 
 
Therefore, after vaccination of growing pigs, under experimental conditions, it has been 
observed a reduction of viremia, lymphoid lesions and amount of PCV2 DNA in tissues, 
oronasal and fecal PCV2 excretion and specific IgM, IgG and NA production, as well as 
cross-protection to both PCV2a and PCV2b (Fenaux et al., 2004; Fort et al., 2008;               
Opriessnig et al., 2008c). Under field conditions, increases of ADWG and percentage of lean 
meat, improvement of feed conversion index and reductions of mortality have been observed 
(Fachinger et al., 2008; Horlen et al., 2008; Kixmoller et al., 2008; Cline et al., 2008;               
King et al., 2008; Opriessnig et al., 2008a, 2008b; Tacker et al., 2008; Desrosiers et al., 2009;                        
Segalés et al., 2009; Martelli et al., 2011), together with increased numbers of PCV2-specific 
IFN-γ secreting cells (IFN-γ SC) suggesting the presence of effector and/or memory T cells 
(Fort et al., 2009; Lyoo et al., 2011).  
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1.3. PCV2 and the immune system 
The specific immune response that develops in pigs after infection by PCV2 is crucial and 
strongly influences the outcome of infection. The animals that develop PMWS often appear to 
be immunosuppressed and unable to eliminate the virus from the blood circulation.  
In the final phase of the clinical manifestation, infected-diseased pigs show extensive 
lymphoid lesions and altered cytokine expression patterns in PBMC and lymphoid organs due 
to their ineffective immune response (Kekarainen et al., 2010).  
Not always PCV2 infection determines the outbreak of clinical signs and immunological 
disorders; in fact, there are asymptomatic animals that show higher virus-specific and 
neutralising antibody titres than PMWS-affected animals. The mechanisms by which PCV2 
can affect the immune responses have not been completely elucidated but recent studies have 
pointed out virus interaction with macrophages and plasmacytoid dendritic cells and the role 
of viral DNA in regulation of immune cell functions. 
 
 
1.3.1 Interaction between PCV2 and immune cells  
In infected animals, cells of the monocytic lineage, including monocytes, macrophages and 
dendritic cells (DC), are most frequently associated to intracellular detection of PCV2 which 
however does not seem to replicate in such cells (Gilpin et al., 2003; Vincent et al., 2003). 
These cells accumulate viral antigen and DNA for extended periods of time, but since viral 
replication is inefficient, they are thought to play a major role in viral persistence and 
transmission (Gilpin et al., 2003; Vincent et al., 2003; Pérez-Martín et al., 2007). 
 
Dendritic cells 
In dendritic cells (DC) the presence of live PCV2 particles leads to different effects depending 
on the cell subpopulation. 
In myeloid dendritic cells (mDC) the virus does not appear to be detrimental to cell survival 
and does not interfere with their maturation; in vitro studies on mDC infected with PCV2 
have indeed proven that the cell expression of major histocompatibility complex (MHC) class 
I and II or cluster of differentiation (CD) 80/86 is not altered by the virus, even after exposure 
to IFN-α and tumor necrosis factor TNF-α (Vincent et al., 2005; Vincent et al., 2003).  
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In the same studies the antigen presenting and processing ability of mDC was reported not to 
be compromised by the infection.  
On the contrary, the interaction of PCV2 with plasmocitoid dendritic cells (pDC), also called 
Natural Interferon Producing cells (NIPC), induces impaired responsiveness to danger signals, 
inhibits interferon (IFN)-α and tumor necrosis factor (TNF)-α production and interferes with 
NIPC maturation as well as paracrine maturation of mDC (Vincent et al., 2005). 
The virus seems not to be transmitted from DC to lymphocytes; this may be a viral strategy to 
escape the host’s immune defence and disseminate exploiting the circulation of DC                
(Vincent et al., 2003). Since asymptomatic piglets produce anti-PCV2 antibodies    
(Krakowka et al., 2002; Ladekjaer-Mikkelsen et al., 2002; Nielsen et al., 2003; Steiner et al., 
2009) and cytotoxic responses (Steiner et al., 2009), the presence of PCV2 in DC does not 
always impair their immunobiological interaction with lymphocytes (Kekarainen et al., 2010). 
 
Monocytes and macrophages 
In vitro and ex vivo studies on the early immune responses following PCV2 infection have 
determined that also monocytes, monocyte-derived macrophages (MdM) and alveolar 
macrophages (AM) are able to internalize PCV2 (Gilpin et al., 2003; Kekarainen et al., 2010); 
in particular, AM phagocyte the virus but, as for DC, viral replication is not strongly 
detectable (Chang et al., 2006). The microbicidal and phagocytic functions of macrophages 
seem to be influenced by PCV2; in addition, increased production of pro-inflammatory 
cytokines such as interleukin (IL)-8 and TNF-α as well as the up-regulation of               
macrophage-derived chemotactic factor-II (AMCF-II), granulocyte colony-stimulating factor 
(G-CSF) and monocyte chemotactic protein-1 (MCP-1) have been reported                               
(Chang et al., 2006; Kekarainen et al., 2010).  
It was also suggested that the PCV2-mediated alteration of AM functionality can support 
opportunistic and secondary pulmonary infections. 
 
Peripheral Blood Mononuclear Cells (PBMC) 
The lymphopenia observed in PMWS-affected pigs is likely due to an indirect effect 
promoted by PCV2 infection in DC and macrophages (Kekarainen et al., 2010). In response 
to recall antigen (PCV2), PBMC from diseased pigs can respond by an increased production 
of IL-10 and IFN-γ compared to PBMC from infected healthy pigs, and display an impaired 
ability to produce IL-4, IL-2 and IFN-γ upon stimulation with antigen (porcine pseudorabies 
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virus; PRV), mitogen (phytohaemagglutinin; PHA) or superantigen (staphylococcal 
enterotoxin B; SEB) (Darwich et al., 2003a; Kekarainen et al., 2008b). Moreover, Kekarainen 
and co-workers (2008b) reported that PCV2 is able to modulate the specific immune 
responses developed by pigs to other pathogens. They showed that IL-12, IFN-α, IFN-γ and 
IL-2 recall responses of PBMC after pseudorabies virus stimulation were down-regulated by 
PCV2, underling that the decreased production of IL-12, IFN-α and IFN-γ could be due to the 
release of PCV2-induced IL-10 by PBMC, CD172a+ cells and bone-marrow derived DC 
(BMDC). 
 
Immune regulatory role for PCV2 DNA 
An immune regulatory role for PCV2 DNA was described for the first time in a study focused 
on the evaluation of the ability of various subpopulations of porcine DC to endocytose PCV2 
from infected PK15A cell lysates (Vincent et al., 2003). Viral genomic ssDNA (Vincent et al., 
2005) and dsDNA replicative intermediates endocytosed from the infected cell lysates 
(Vincent et al., 2007) were found in DC. Vincent et al. (2007) theorised that these DNA 
elements can interact with endosomal toll-like receptors (TLR) or cytosolic helicases inducing 
impairment of cytokines produced by pDC. These findings suggested the presence of DNA 
sequences in the PCV2 genome capable to interfere with DC and immune defences.  
Several CpG motifs have been characterised in PCV2 genome revealing synthetic 
oligodeoxynucleotides (ODN) sequences able to modulate cytokine production of porcine 
PBMC cultures by induction or inhibition (Hasslung Wikström et al., 2003; Kekarainen et al., 
2008a). The effect of these ODN was also analysed on porcine PBMC recall responses and 
cytokine production by BMDC (Kekarainen et al., 2008a; Kekarainen et al., 2010).  
It has been found that some ODN induce a decrease in the IFN-α response of BMDC upon 
PRV stimulation. The majority of the inhibitory ODN is located within the Rep region of the 
PCV2 genome but none of them, conversely to the whole virus, have been demonstrated to 
induce IL-10 production in PBMC (Kekarainen et al., 2008b). However, the presence of ODN 
in PBMC cultures appeared to decrease the IFN-γ or IL-2 responses to recall antigens 
(Kekarainen et al., 2010). 
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1.3.2 Humoral response 
Immunity against PCV2 in piglets can be transmitted as maternal antibodies by the sow. This 
passive immunity has been demonstrated to protect from PMWS onset in a dose-dependent 
manner (Rose et al., 2007). Colustrum administration is an important practice to induce 
protection of the offspring but also the PCV2 infection status of the sow has been 
demonstrated to be crucial. With regards to these evidence Calsamiglia et al. (2007) showed 
that, from sows with low levels of PCV2 antibodies, there is a higher percentage of piglets 
that result PMWS-affected. Nevertheless, it is important to remind that the presence of PCV2 
antibodies is not necessarily protective because not all antibodies are neutralizing upon PCV2 
infection. 
 
In experimentally infected pigs, seroconversion commonly occurs between 14 and 28 days 
post-inoculation (dpi) (Allan et al., 1999a; Balasch et al., 1999; Krakowka et al., 2001;  
Meerts et al., 2005; Segalés et al., 2005). More specifically, several studies have observed that 
PMWS-affected pigs seroconvert later (Fort et al., 2007; Meerts et al., 2006;                             
Bolin et al., 2001; Okuda et al., 2003), or show a weak response characterised by lower 
antibody titres at 21 dpi than in subclinically PCV2-infected animals (Meerts et al., 2006; 
Kekarainen et al., 2010).  
The different immunoglobulin isotypes follow the course of total antibody titres                       
(Meerts et al., 2006); in PCV2-subclinically infected pigs also the titres of virus neutralising 
antibodies (NA) follow this course (Meerts et al., 2006; Fort et al., 2007). Contrarily, the 
impaired humoral response of diseased pigs is characterised by decreased production of total 
antibodies and low levels of NA that subsequently result in a higher viral load                             
(Fort et al., 2007; Meerts et al., 2005).  
 
Under field conditions, the first protection against PCV2 is represented by passive immunity 
transferred by the sow; this protection lasts during the lactating and nursery periods and is 
depleted by the end of nursery and the beginning of fattening periods (Rodriguez-Arrioja et 
al., 2002; Rose et al., 2002; Larochelle et al., 2003). Active seroconversion to PCV2 usually 
occurs between 7-12 weeks of age (Segalés et al., 2005) and anti-PCV2 antibodies generally 
last until at least 28 weeks of age (Rodriguez-Arrioja et al., 2002). An impaired humoral 
response may extend the period between the decline of maternal immunity and the onset of 
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active seroconversion in piglets, thus increasing the probability to develop PMWS upon 
PCV2 infection.  
It has also been showed that the titres of anti-PCV2 IgM overtime, in contrast with the course 
of IgG1, IgG2 and IgA antibodies, remain lower in diseased pigs than in subclinical infected 
animals (Meerts et al., 2006). 
 
In case of PCV2 infection, the adaptive humoral immune responses play a crucial role in 
determining whether or not the outbreak of PMWS occurs despite other immune mechanisms 
are required to obtain complete viral clearance. 
 
 
1.3.3 Cell-mediated immune responses 
The role of adaptive cell-mediated responses in controlling PCV2 infection is still less studied 
compared to humoral responses (Kekarainen et al., 2010). However, the few studies that have 
already been performed provide relevant information. On gnotobiotic experimentally infected 
pigs, it has been demonstrated that the treatment with cyclosporine A (CyA)                                   
(i.e. an immunosuppressing agent), before PCV2 inoculation determines an increase of viral 
replication (Krakowka et al., 2002; Meerts et al., 2005). The IFN-γ mRNA expression levels 
in PBMC from these PCV2-inoculated animals resulted to be correlated with viral replication 
and immunosuppressed status induced by CyA, suggesting that a higher expression of IFN-γ 
can help pigs be less susceptible to PCV2 replication (Meerts et al., 2005). 
Other studies have analysed the development of IFN-γ secreting cells (IFN-γ SC) in either 
conventional colostrum-fed pigs infected with PCV2 alone (Fort et al., 2009a) or in 
colostrum-fed specific pathogen free (SPF) pigs infected with PCV2 together with Porcine 
parvovirus as a potential triggering factor for PMWS development (Steiner et al., 2009). 
Caesarean-derived colostrum deprived (CD/CD) pigs infected with PCV2 along with 
lipopolysaccharide (LPS) (Fort et al., 2009a) have also been analysed (Kekarainen et al., 
2010). The results of these three studies underline the key role of IFN-γ SC in developing the 
anti-PCV2 adaptive cellular response.  
 
It has been found that vaccination treatements are effective in reducing PCV2 load in the 
blood, concomitantly with the development of a virus-specific humoral response, especially 
mediated by NA both in field (Kixmoller et al., 2008) and experimental (Opriessnig et al., 
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2008c) infection models. In addiction, it has been shown the onset of a cellular response in 
terms of PCV2-specific IFN-γ SC in pigs vaccinated with a PCV2 sub-unit vaccine, 
experimentally infected (Fort et al., 2009b). Thus, we can assume that if at least one of these 
responses fails, viral clearance will be impaired, and the risk of developing PMWS can 
increase. However, the cell-mediated responses of pigs to PCV2 infection, although in cases 
of previous vaccination, have still to be thoroughly investigated. 
 
 
1.3.4 PCV2 modulation of cytokine profiles 
Cytokine mRNA expression profiles can be important to characterise the host’s immune 
responses that occur upon viral infections, therefore pro-inflammatory and immune cytokine 
production has been recently investigated in different PMWS and infection models (Chae et 
al., 2011; Kekarainen et al., 2008a, 2010). With regards to lymphoid tissues, increased levels 
of IL-10 mRNA expression were found in the thymus and decreased levels of IL-4 and IL-2 
were detected in tonsils and spleen from PMWS-affected pigs (Darwich et al., 2003b).  
Opposed results were described for IFN-γ: low mRNA expression levels were detected in 
inguinal and tracheo-bronchial lymph nodes whereas high expression was shown in tonsils 
(Darwich et al., 2003b; Zhang et al., 2010). 
An increase of IL-10, together with slight increases in IL-8, IFN-γ and TNF-α and a decrease 
in IL-2 and IL-4 mRNA levels, were also detected in PBMC from PCV2 naturally infected 
pigs (Sipos et al., 2004).  
Significantly higher expression of IL-10 was found in PCV2-infected lymphoid tissues 
compared to uninfected control tissues (Doster et al., 2010); furthermore, serum IL-10 was 
detected in pigs developing severe PMWS and the increased expression of this cytokine has 
been reported to be correlated with viremia in subclinically PCV2-infected pigs (Stevenson et 
al., 2006).  
Increased serum levels of the acute phase proteins (APP) haptoglobin, pig major acute phase 
protein (pig-MAP), C-reactive protein (CRP), serum amyloid A (SAA) and albumin were also 
reported in PMWS-affected pigs (Parra et al., 2006; Stevenson et al., 2006; Segalés et al., 
2004). 
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The production of cytokines and the balance between pro-inflammatory, pro-immune and 
regulatory cytokines play a pivotal role in eliciting the innate response as well as in priming 
and coordinating the adaptive immune response.  
For this reason the study of cytokines appears to be an important tool to evaluate the cellular 
immune response against PCV2. The above mentioned evidence suggest a severe 
immunosuppression in PMWS-affected pigs but the mechanisms determining the 
immunological impairment, that is not detectable in subclinically infected animals, are still 
poorly understood (Kekarainen et al., 2010). 
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Management strategies, control of coinfections and vaccination are at present the measures by 
which PMWS and Porcine Circovirus Diseases (PCVD) are controlled. 
Nowadays PCV2 vaccination represents one of the major strategies to overcome PCV2 
infections in the herds and therefore several commercial vaccines are available.  
All PCV2 vaccines currently available on the market have been tested under field conditions 
resulting to be effective and helpful in decreasing mortality and cull rates and significantly 
improving the average daily weight gain (ADWG), concomitantly with decreasing the 
frequency of coinfections in herds affected with PMWS (Cline et al., 2008; Desrosiers et al., 
2009; Fachinger et al., 2008; Horlen et al., 2008; King et al., 2008; Kixmoller et al., 2008; 
Opriessnig et al., 2008b,c; Tacker et al., 2008; Segalés et al., 2009; Pérez-Martin, 2010).  
Even if PCV2 vaccines are effective in reducing the viremia burden and viral-induced specific 
lymphoid lesions, the mechanisms by which they are able to elicit protective immunity are not 
thoroughly known (Fachinger et al., 2008; Fort et al., 2008; Horlen et al., 2008). 
However, since PCV2 can evade immune surveillance and PCV2 infection is often associated 
with co-infections in the field (e.g. porcine reproductive and respiratory syndrome virus - 
PRRSV, Mycoplasma hyopenumoniae - M. hyo.), it is not easy to obtain a complete resolution 
of the disease.  
Therefore, the improvement of vaccine formulations and administration strategies represents 
one of the main areas of interest in PCV2 vaccinology. 
The activation of the host’s immune response has been proved to be one of the primary 
factors modulating the progression of the disease. Several studies have shown the importance 
of the antibody response, especially that mediated by neutralizing antibodies (NA), in coping 
with infection. Also the cell-mediated immune response seems to play a key role in 
preventing viral replication and counteract viral diffusion, despite many immune mechanisms 
which sustain virus clearance and the resolution of infection are still unclear                            
(Fenaux et al., 2004b; Kixmoller et al., 2008; Fort et al., 2009a, 2009b; Steiner et al., 2009; 
Pérez-Martin et al., 2010). 
For these reasons, several studies have been performed to investigate the mechanisms by 
which PCV2 can elude the immune defences in pigs and to develop new vaccination 
strategies aimed at inducing efficient immune activation and immune protection upon 
infection. The effects of vaccination treatments are related to total and neutralising antibody 
responses as well as to cell-mediated immunity (Larochelle et al., 2003; Fort et al., 2008, 
2009a; Kixmoller et al., 2008; Opriessnig et al., 2008b, 2008c).  
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The humoral immunity to PCV2 infection were characterised, by most of the published 
reports, through the detection of total anti-PCV2 antibodies, showing seroconversion that 
occurs either in subclinically or non-PMWS infected and PMWS-affected pigs (Rodrıiguez-
Arrioja et al., 2000; Sibila et al., 2004; Grau-Roma et al., 2009).  
On the other hand, the role and mechanisms of the adaptive cell-mediated immune response 
in controlling PCV2 infection and the related diseases have not been clearly elucidated, 
particularly under field conditions. Previous reports based on laboratory trials describe that 
viral clearance may be mediated by cell-mediated immunity, measured by the number of 
PCV2-specific interferon-γ (IFN-γ) secreting cells (SC), together with neutralising antibodies 
(Fort et al., 2009a, 2009b) and that the load and the extent of viral replication may influence 
the intensity of the cell-mediated immune response. 
Specifically PCV2 vaccines showed to induce an intense antibody and cellular responses but 
data regarding the immune responses under field conditions and underlying vaccine-induced 
protection are still incomplete.These aspects are worth investigating under field conditions 
both in diseased pigs naturally infected by PCV2 in the presence of coinfections and in 
vaccinated animals showing no or few clinical signs.  
Furthermore, the modulation of cytokine patterns are important to categorize the host immune 
responses that occur during viral infections; for successful resolution of infection, efficient 
activation of innate/inflammatory and acquired immunity is required to block pathogen 
replication and invasion, as well as to promote tissue clearance of the pathogens and/or 
infected cells. The production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-8) and the 
balance between pro-immune (IFN-γ) and regulatory (IL-10) cytokines play a pivotal role in 
eliciting the innate response as well as in priming and coordinating the adaptive immune 
response. However, if production is impaired, the innate response will be delayed and 
inefficient in clearing the pathogen (Borghetti et al., 2010). 
Therefore, pro-inflammatory and immune cytokine production has been investigated in 
different PMWS and infection models. Increased levels of IL-10 mRNA expression were 
found in the thymus and decreased levels of IL-4 and IL-2 were detected in the tonsils and 
spleen from PMWS-affected pigs (Sipos et al., 2004). Contrary results were described for 
IFN-γ: low mRNA expression levels were detected in inguinal and tracheobronchial lymph 
nodes whereas high expression was shown in the tonsils (Darwich et al., 2003b; Zhang et al., 
2010). An increase of IL-10, together with slight increases of IL-8, IFN-γ and TNF-α and a 
decrease of IL-2 and IL-4 mRNA levels, were also detected in PBMC from naturally                 
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PCV2-infected pigs (Sipos et al., 2004). Furthermore, serum IL-10 was associated with 
subclinically PCV2-infected pigs or pigs developing severe PMWS (Stevenson et al., 2006). 
A significantly higher expression of IL-10 was also found in PCV2-infected lymphoid tissues 
compared to uninfected control tissues (Doster et al. 2010). 
Cytokine secretion may play a key role in evaluating the cellular immune response against 
PCV2, but the cytokine modulation investigated so far in different organs has not provided 
univocal results likely due to different working conditions.  
Taking into account the above mentioned features, the aim of the present thesis is to 
investigate the efficacy of PCV2 vaccination under field conditions in vaccinated and 
unvaccinated pigs upon PCV2 natural infection and associated PCVD in terms of clinical 
protection and development of the humoral and cell-mediated immune response.  
 
The specific objectives of the present study are the following: 
 
1. the evaluation of the efficacy of a one-dose PCV2 subunit vaccine based on the 
PCV2 Cap protein expressed in a baculovirus system (Porcilis PCV®) at two 
different farms where PCVD was present, in terms of clinical protection;  
2. the assessment of the vaccine immunogenicity in vaccinated and unvaccinated pigs 
exposed to PCV2 natural infection in terms of development of humoral (total  
PCV2-specific antibodies) and cell-mediated (PCV2-specific IFN-γ secreting cells) 
immune responses;  
3. the quantitative modulation of pro-inflammatory and immune cytokines in 
vaccinated and unvaccinated pigs exposed to natural PCV2 infection, in relation to 
the onset of PCV2 viremia burden and PMWS clinical signs. 
 
The results regarding the evaluation of PCV2 vaccine efficacy as clinical protection and 
humoral and cell-mediated immune responses were published in Martelli P., Ferrari L., 
Morganti M., De Angelis E., Bonilauri P., Guazzetti S., Caleffi A., Borghetti P. Veterinary 
Microbiology. 2011; 149(3-4): 339-351. 
 
The data concerning the study of cytokine immune modulation were submitted to the journal 
“Comparative Immunology, Microbiology and Infectious Diseases” as Borghetti P., Morganti 
M., Ferrari L., De Angelis E., Saleri R., Cavalli V., Corradi A., Martelli P. Modulation of   
pro-inflammatory and immune cytokines in PBMC of vaccinated and unvaccinated pigs 
exposed to porcine circovirus type 2 (PCV2) natural infection (submitted, 2011).  
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3.1. Materials and methods 
3.1.1. Selection of farms 
The study was conducted in the Northern part of Italy at two farms with history of PMWS.  
In both herds, at approximately 15-20 weeks of age, clinical signs of PWMS characterised by 
wasting, respiratory signs and growth retardation were mainly associated with a marked 
increase in the mortality rate. The diagnosis fulfilled the internationally accepted disease case 
definition, including clinical signs, gross lesions, histopathologic findings, and presence of 
PCV2 in lymphoid lesions (Segale´ s et al., 2005). Seropositivity to PCV2 in all categories of 
animals (replacement gilts, sows, nursery pigs, growers, and fatteners) was demonstrated. 
Before the start of the study, 5 wasted pigs were autopsied at each farm and the diagnosis was 
reconfirmed.  
FARM 1 was a 900-sow farrow-to-finish herd that, in the previous year, experienced a                  
6% and an 8% mortality rate in the nursery and fattening periods, respectively. This farm was 
seronegative for Aujeszky’s disease virus (ADV) and seropositive for PRRSV,                              
M. hyopneumoniae and A. pleuropneumoniae. Low titres of antibodies at haemagglutination 
inhibition (HI) to SIV were obtained from some samples and were not informative.  
FARM 2 was a three-site farm with 1850 sows experiencing a 2% and a 10% mortality rate in 
the nursery and fattening periods, respectively. Seropositivity to PRRSV and                                  
M. hyopneumoniae and seronegativity to ADV were found.  
Sows of both herds were vaccinated for Aujeszky’s disease (3 times/year), porcine parvovirus 
and erysipelas (both at mid-lactation). Piglets were vaccinated for Aujeszky’s disease 
according to the National Control Program. 
 
The protocols and results of the evaluation of PCV2 vaccine efficacy as clinical protection 
and humoral and cell-mediated immune responses are published in Martelli P., Ferrari L., 
Morganti M.,  De Angelis E., Bonilauri P., Guazzetti S., Caleffi A., Borghetti P. Veterinary  
Microbiology. 2011; 149(3-4): 339-351. 
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3.1.2. Animals and experimental design 
This study was a double-blind, randomised, controlled field trial performed according to the 
principles of ‘‘Good Clinical Practice’’ and included 818 piglets (males and females). The 
day before inclusion, piglets were identified, double ear-tagged and assigned to two treatment 
groups [unvaccinated = placebo/control (group A) and PCV2-vaccinated (group B)] as they 
came to hand sequentially (A–B–A–B–A–B...). The sequential allocation was continued over 
the litters. The identification of the sow and the date of birth of the piglets were recorded. 
At inclusion (weaning: 21±3 days of age), vaccinated animals (group B) received one dose of 
a commercial PCV2a-based subunit vaccine (Porcilis PCV1 - Intervet/Schering-Plough 
Animal Health, Boxmeer, The Netherlands) containing the PCV2 capsid (Cap) protein 
expressed in a baculovirus system suspended in an α-tocopherol(+ liquid paraffin)-based 
adjuvant administered intramuscularly (2 ml) in the right neck muscle according to the 
manufacturer’s recommendations. The same amount of adjuvant was injected into the same 
anatomic location in control unvaccinated pigs (group A).  
The administration of vaccine and placebo was performed using a double-blind fashion 
system for both farms. Animals of both groups were injected at weaning and moved to the 
nursery units. Table 1 lists the details of the studied animals at the time of inclusion.  
 
 
Table 1. Details of the animals under study at the time of inclusion. Group A: placebo/control pigs; 
group B: PCV2-vaccinated pigs. 
 
 
                      Farm 1           
     Group A Group B 
                      Farm 2 
      Group A 
 
Group B 
 
Pigs at inclusion 
 
206 
 
205 204  203 
 
Males–females 
 
97–109 
 
112–93 109–95  108–95 
 
Total pigs 
 
 411  
 
407 
 
 
Litters 
 
 
43 
  
40 
 
 
Weighed at inclusion 
 
206 
 
205 204  203 
 
Bled at inclusion 
 
22 
 
22 22 
 
22 
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After weaning, pigs from both treatment groups were kept in mixed groups until the end of 
the trial, when animals were sent to the slaughterhouse (at approximately 9 months of age).  
Treatments, housing, husbandry, and feeding were conformed to the European Union 
Guidelines and identical for both experimental groups at each farm. At each accommodation 
change, pigs were commingled according to usual farm procedures.  
Pigs were clinically monitored on a weekly basis from the administration of vaccine or 
placebo until slaughter. From one week post-vaccination, pigs were monitored daily for 
vaccination reactions. Individual live body weights of all animals enrolled in the study were 
measured the day before inclusion and at 12 and 26 weeks of age. The average daily weight 
gain (ADWG) was calculated based on the ADWG of animals being alive at the end of each 
weighing period. Carcass weight was recorded at the slaughterhouse in pigs from farm 2.  
If concomitant treatments (injections) were used, the number of animals treated within each 
group and the duration of treatment were recorded. The number of relapsed animals 
(retreatments) were also considered. The number of injections was used as a parameter to 
evaluate morbidity.  
Dead animals or those that had to be euthanised for reasons of animal welfare were recorded 
daily.  
In both herds, at inclusion (day of vaccination, 3 weeks of age), blood samples were collected 
from 2 piglets of each pluriparous sow litter: one for each treatment group, up to 44                       
(22 piglets for each treatment group). These piglets were identified by a progressively 
numbered ear tag.  
 
Moreover, in piglets from FARM 1, blood samples were taken at 4 [+1 week post-
vaccination (PV)], 5 (+2 weeks PV), 6 (+3 weeks PV), 7 (+4 weeks PV), 9 (+6 weeks PV),   
12 (+9 weeks PV), 15 (+12 weeks PV), 16 (+13 weeks PV), 17 (+14 weeks PV),                                
18 (+15 weeks PV), 19 (+16 weeks PV), 20 (+17 weeks PV), 22 (+19 weeks PV),                           
26 (+23 weeks PV), and 35 (+32 weeks PV) weeks of age.  
 
In FARM 2, blood samples were collected at vaccination (3 weeks of age), at 4 (+1 week 
PV), 6 (+3 weeks PV), 12 (+9 weeks PV), 16 (+13 weeks PV), 18 (+15 weeks PV),                         
20 (+17 weeks PV), 22 (+19 weeks PV), 24 (+21 weeks PV), 26 (+23 weeks PV), and                   
35 (+32 weeks PV) weeks of age. 
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3.1.3. Evaluation of gross pathology, histopathology, and immunohistochemistry  
The objective of the pathologic studies was to establish the PMWS diagnosis in all pigs from 
both farms that died, those needing euthanasia, and runts during the entire study period. These 
pigs underwent gross pathologic examination and histopathology within 24 hours.  
Samples from inguinal, mesenteric and mediastinic lymph nodes were removed from 
necropsied pigs and fixed in 10% buffered formalin. Fixed samples were processed for 
routine histopathology and 5-µm thick sections were stained with hematoxylin and eosin to be 
examined for lesions compatible with PMWS.  
The diagnosis of PMWS was made when all three criteria of the accepted international 
individual case definition for the disease were present, that are: 1) clinical signs, mainly 
including wasting; 2) moderate-to-severe lymphoid lesions; 3) moderate-to-high amounts of 
PCV2 in those lesions.  
The amount of PCV2 in tissue samples was also assessed by real-time quantitative PCR 
(qPCR) using the methods reported by Olvera et al. (2004).  
Immunohistochemistry for detection of PCV2-specific antigen was performed on formalin-
fixed and paraffin embedded sections of inguinal, mediastinal, and mesenteric lymph nodes 
using a rabbit polyclonal antiserum (Sorden, 2000). PCV2 antigen scoring was performed by 
a pathologist in a blind manner using the score range in accordance with Opriessnig et al. 
(2004). 
 
 
3.1.4. Extraction and qPCR detection of PCV2 DNA from tissue samples and serum 
In order to detect and quantify the PCV2 DNA by PCR, DNA was firstly extracted from                 
200 µl of serum or 200 µl of 1:10 phosphate-buffered saline (PBS) homogenate of lymph 
node tissue, by using TRIzol LS (Invitrogen, San Diego, CA,USA) following the 
manufacturer’s instructions. The DNA obtained was suspended in 50 µl of 
diethylpyrocarbonate (DEPC)-treated water. Real-time qPCR was carried out using a 
LightCycler 1.5 (Roche, Basel-CH). Real-time qPCR was performed using primers and 
probes according to Olvera et al. (2004). Results of the qPCR were expressed as number of 
PCV2 genome copies per milliliter of serum or gram of tissue. 
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Table 2. Properties, sequence and localisation of primers and probes designed for the PCV2               
real-time PCR by primer express (Olvera et al., 2004).  
 
 
Tm (◦C) %GC bp Sequences (5’→ 3’) Location in  PCV2 genome 
PCV2 F 60 63 19 CCAGGAGGGCGTTGTGACT 1535 → 1553 
PCV2 R 59 55 20 CGCTACCGTTGGAGAAGGAA 1633 → 1614 
PCV2 P 68 52 25 AATGGCATCTTCAACACCCGCCTCT 1612 → 1592 
 
PCV2 F = primer forward, PCV2 R = primer reverse, PCV2 P = probe, Tm = melting temperature. 
 
 
 
3.1.5. Serology 
 
3.1.5.1. PCV2-specific antibody titres 
The anti-PCV2 antibody titres in sera were determined using a blocking enzyme-linked 
immunosorbent assay (ELISA). The wells of microtitre plates were coated overnight at 2-8°C 
with baculovirus-expressed PCV2 ORF2 antigen. Subsequently, the plates were washed and 
blocked with casein buffer at 37°C for 1 h. After washing, serial 4-fold dilutions of the test 
sera were added. An internal standard serum and a positive and negative standard serum were 
run in parallel in each plate. The sera were incubated for 1 h at 37°C and the plates were then 
washed before the addition of a PCV2-specific biotinylated monoclonal antibody (mAb). 
After 1 h incubation at 37°C, plates were washed again and incubated for 45 min at 37°C with 
avidin-labeled horseradish peroxidase (APO; DAKO A/S, Glostrup, Denmark). After 
washing, a 3,3’,5,5’-tetramethylbenzidine (TMB) substrate solution was added and incubated 
for 15 min. at room temperature. The reaction was stopped by the addition of 4 N sulphuric 
acid and the extinction was read in a photometer fitted with a 450-nm filter                           
(Titertek Multiscan Plus MK 11 – Titertek Instruments Inc., Huntsville, AL, USA) within              
15 min. after the reaction was stopped. The raw data were processed and titres were calculated 
using the Multi-calc program with a cut-off extinction value set at 50% blocking. The cut-off 
extinction was calculated from the positive and negative standard serum and titres were 
expressed as log2. 
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3.1.5.2. Antibody titres to other infectious agents 
The presence of antibodies to PRRSV and sample/positive (S/P) ratios were determined using 
a commercially available ELISA kit (HerdChek1 Porcine Reproductive and Respiratory 
Syndrome Antibody Test Kit, IDEXX Laboratories, Westbrook, ME, USA) according to the 
manufacturer’s instructions. The Herd Check1 test bases the sample classification on the S/P 
ratio, which is defined as (sample O.D. - negative control O.D.) / (positive control O.D.- 
negative control O.D.). Sample to positive control ratios ≥ 0.4 were considered positive. 
Antibodies to M. hyopneumoniae were evaluated by a commercially available ELISA test 
(Herd Check1 M. hyopneumoniae, IDEXX Laboratories). The presence of antibodies to gE 
glycoprotein of ADV was measured using a commercially available ELISA kit [HerdChek1 
PRV g1 (gE) test kit, IDEXX Laboratories] according to the manufacturer’s instructions.  
A commercial ELISA kit (CHEKIT-APP-Apx IV ELISA test kit, IDEXX Laboratories) was 
used for the detection of antibodies against A. pleuropneumoniae. Serology to swine influenza 
virus (SIV) was performed by using HI. 
 
 
3.1.6. ELISpot for determination of PCV2-specific IFN-γ secreting cells (SC) 
An IFN-γ ELISpot assay was performed according to Martelli et al. (2009) in order to 
evaluate the frequencies of IFN-γ SC in the peripheral blood of pigs from farm 1. 
The assay was performed in MultiScreen®HTS-IP plates (MSIPS4510 – Millipore) coated with 
10 µg/ml anti-pig IFN-γ mAb (P2G10, BD, Biosciences, Franklinlakes, NJ, USA) at 4°C 
overnight. After incubation, plates were washed with sterile PBS and blocked with                  
RPMI-1640 supplemented with 10% foetal bovine serum (FBS) for 2 h at 37°C, 5% CO2.  
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient using a 
Histopaque-1.077® solution and plated at 2 x 105 cells/well in RPMI-1640 + 10% FBS.  
For the ex vivo antigen recall, a whole PCV2 strain (I12/11) at 0.1 multiplicity of infection 
(MOI) was used as stimulus, in RPMI-1640 + 10% FBS, for 20 h at 37°C, 5% CO2; the SC 
response was also evaluated at 0.05 and 0.25 MOI. In all samples, PBMC were > 98% viable 
as confirmed by Trypan blue exclusion. Afterward, cells were removed by washing with PBS 
+ 0.05% Tween-20 (PBST) and the plates were incubated for 1 h at 37°C with 0.5 µg/ml              
anti-pig IFN-γ biotin-labeled mAb (P2C11, BD). After washing, plates were incubated with 
1:750 alkaline phosphatise (AP)-conjugated anti-biotin mAb in PBS + 0.5% BSA for 1 h at 
37°C. Plates were finally incubated for 7 min. with a BCIP/NBT solution (BioRad, Hercules, 
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CA, USA) in order to let spots develop and the reaction was stopped with distilled water. The 
frequencies of PCV2-specific IFN-γ SC were determined using an AID® ELISpot Reader 
(AID® ELISpot Software v.3.5). As a positive control, 1 x 105 PBMC/well were incubated 
with phytohemagglutinin (PHA, 10 µg/ml); as a negative control, 2 x 105 PBMC were 
incubated in the absence of antigen (mock stimulus: supernatant of non-PCV2-infected PK-15 
cells). The background values (number of spots in negative control wells) were subtracted 
from the respective counts of the stimulated cells and the immune responses were expressed 
as number of IFN-γ SC per million PBMC (IFN-γ SC/106 PBMC).  
The IFN-γ SC responses were also classified as responsiveness categories on the basis of the 
responses observed in the present study and with regards to categories reported in literature 
(Fort et al, 2009b; Ferrari et al., 2011).  
Specifically the responsiveness categories identified were: 
• 0-40 IFN-γ SC/106 PBMC = no-poor 
• 45-100 IFN-γ SC/106 PBMC = low 
• 105-200 IFN-γ SC/106 PBMC = intermediate 
• 205-400 IFN-γ SC/106 PBMC = high 
• ≥ 405 IFN-γ SC/106 PBMC = very high 
 
Particularly, the range for the “no-poor” category was determined based on the responses 
observed in unvaccinated animals throughout the post-vaccination period and data in 
literature (Pérez-Martin et al., 2010).  
 
 
3.1.7. Evaluation of cytokine gene expression  
Blood samples collected from 10 PCV2-vaccinated and 20 non-vaccinated pigs were used as 
source of swine peripheral blood mononuclear cells (PBMC) in order to determine mRNA 
expression levels of relevant pro-inflammatory and pro-immune cytokines.  
At the end of the trial, taking into consideration the time of the onset of viremia and the 
appearance of clinical signs, blood samples taken at 16 (before infection and the desease 
onset), 19 and 22 weeks of age (during PCV2 viremia and disease outcome) were used for the 
quantification of cytokine expression. 
For the purposes of this study, the thirty sampled pigs were attributed to three different 
groups: 1) non vaccinated and spontaneously PCV2 infected animals (N = 5) that showed 
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over clinical signs attributable to PMWS (Ctrl-PMWS+); 2) non-vaccinated and 
spontaneously PCV2 infected animals (N = 15) that did not develop PMWS (Ctrl);                             
3) vaccinated pigs (N = 10) that were not infected and did not develop PMWS (PCV2-vac).  
Moreover, to establish an association between cytokine expression and viremia burden, each 
of the above mentionated groups was analysed dividing the animals in three different 
subgroups based on viremia: non-viremic pigs (NV), pigs with viremia <106 (V<106) and pigs 
with viremia ≥106 (V≥106) viral genome copy number / ml of serum. 
 
 
3.1.7.1 Isolation of PBMC and extraction of total RNA 
mRNA expression levels of relevant pro-inflammatory (IL-8, TNF-α, IL-1β) and immune 
(IFN-γ, IL-10) cytokines were determined in swine peripheral blood mononuclear cells 
(PBMC) after isolation by density gradient using Histopaque-1077® (Sigma) and total RNA 
extraction by TRI-reagent® (Ambion) according to the manufacturer’s instructions; purity and 
concentration were assessed by UV spectrophotometry at 260/280 and 260 nm respectively 
(GeneQuant Pro®, Amersham Pharmacia Biotech-GE Healthcare Life Sciences, Little 
Chalfont, UK). 
 
 
3.1.7.2. RNA reverse transcription (RT) 
Total RNA (1 µg) was reverse transcripted using a High-capacity cDNA Reverse 
Transcription kit (Applied Biosystems). The reverse transcription was performed by using a 
StepOne™ thermocycler (Applied Biosystems, StepOne software v. 2.1) and, according to the 
manufacturer's established procedures, under the following thermal conditions: 10 min.                  
at 25°C, 120 min. at 37°C followed by 5 min. at 85°C and a pre-storage at 4°C. All cDNA 
samples were stored at -20°C until PCR was performed. 
 
 
3.1.7.3 Quantification of cytokine mRNA by quantitative PCR 
The obtained cDNA was used (20 ng) as a template for real-time PCR (qPCR) performed by 
using a StepOne™ thermocycler (Applied Biosystems, StepOne software v. 2.1). The cDNA 
(20 ng/20 µl) was amplified in duplicate with Fast SYBR® Green Master Mix (Applied 
Biosystems) along with specific sets of primers at optimized concentrations.  
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The primers were designed based on published gene sequences (Royaee et al., 2004; 
Meissonnier et al., 2008; von der Hardt et al., 2004) or by using Primer Express® software for 
primer design (purchased from MWG). Details of each primer set for detection of cytokine 
gene expression are reported in Table 3. 
The reference gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was selected as 
endogenous control according to Fisher et al. (2006) and Borghetti et al. (2010).  
Samples were kept at 95°C for 20 sec. (hold step) to allow DNA polymerase activation and 
then subjected to 40 cycles constituted of a denaturation step at 95°C for 3 sec. followed by an 
annealing/extension step at 60°C for 30 sec. (Applied Biosystems “Fast” real-time PCR 
protocol). Fluorescence due to SYBR® Green incorporation was acquired at the end of the 
extension step. A no-template control was included in each experiment.  
A melting curve analysis for specific amplification control was performed (from 60°C to 
95°C) at the end of the amplification cycles.  
 
Table 3. Details of the primer sequences of pig pro-inflammatory (IL-8, TNF-α, IL-1β) and immune 
(IFN-γ, IL-10) cytokines used for quantitative SYBR® Green real-time PCR. GAPDH gene was used 
as endogenous control gene. 
 
Gene  
Primer sequence 
(forward – reverse) 
Concentration 
(nM) 
 
Amplified 
product  
(bp) 
for 5’-CCGTGTCAACATGACTTCCAA-3’ 300 IL-8 
(Royaee et al., 2004) rev 5’-GCCTCACAGAGAGCTGCAGAA-3’ 300 
 
75 
for 5’-ACTGCACTTCGAGGTTATCGG-3’ 300 TNF-α 
(Meissonnier et al., 2008) rev 5’-GGCGACGGGCTTATCTGA-3’ 300 
 
118 
for 5’-ATGCTGAAGGCTCTCCACCTC-3’ 300 IL-1β 
(von der Hardt et al., 2004) rev 5’-TTGTTGCTATCATCTCCTTGCAC-3’ 300 
 
89 
for 5’-TGGTAGCTCTGGGAAACTGAATG-3’ 300 IFN-γ 
(Royaee et al., 2004) rev 5’-GGCTTTGCGCTGGATCTG-3’ 300 
 
79 
for 5’-TGAGAACAGCTGCATCCACTTC-3’ 300 IL-10 
(Royaee et al., 2004) rev 5’-TCTGGTCCTTCGTTTGAAAGAAA-3’ 300 
 
114 
for 5’-GGTGAAGGTCGGAGTGAACG-3’ 300 GAPDH 
(Primer Express) rev 5’-GCCAGAGTTAAAAGCAGCCCT-3’ 300 
 
70 
 
Data were analyzed according to the 2-∆∆Ct method; in the present experiment the expression 
levels of each cytokine, normalized to the GAPDH cDNA amount and expressed as relative 
quantities (RQ), were calculated with regards to some PCV2-vaccinated uninfected animals 
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early in the post-exposure (PE) period. In order to apply the 2-∆∆Ct method, because of the 
required normalisation step, it was necessary to first assess that the efficiency of the cytokine 
primers was comparable to that of the housekeeping gene. In this regard, a concentration 
range for each primer pair was tested by serial dilution of a cDNA sample in which both the 
housekeeping and target genes could be easily amplified. Only primers showing a comparable 
amplification efficiency to that of GAPDH were used. 
 
 
3.1.8. Statistical analysis 
To estimate the effect of vaccination on the probability of a pig of becoming viremic, a mixed 
effect logistic regression model was fitted to take into account the non independence of the 
repeated measures on the same subjects and the effect of the sow (litter effect). These two 
variables were treated as ‘‘random effects’’ in the model, whereas the effect of the farm (two 
levels), sex, time, and treatment and their interactions were considered as ‘‘fixed effects’’. 
The effect of the time x treatment interaction was highly significant (P = 0.0146), indicating 
that these results are not attributable to chance alone. The package ‘‘lme4’’was used (Bates 
and Sarkar, 2007; lme4: linear mixed effects models using S4 classes, R package version 
0.999375-32). To estimate the effect of vaccination on the probability of a pig suffering from 
PCVD and being lost, considering the competing risks of dying or being lost from other 
causes, a stratified Cox proportional hazard model was fitted, according to Putter et al. (2007) 
and Therneau and Grambsch (2000). The model accounted also for the ‘‘cluster’’ effect of the 
sow (‘‘litter effect’’) because piglets from the same litter are expected to have similar clinical 
histories. The effect of the vaccination on weight gain was evaluated within a mixed effects 
model, given the hierarchical structure of the experiment (Pinheiro and Bates, 2000).  
Vaccine efficacy was measured by the proportion of cases that it prevented, comparing 
disease outcome in the treated versus control groups. Efficacy was presented here as one-risk 
ratio (the so-called preventive fraction), which gives the risk in the vaccinated group as a 
proportion of the risk in the control group (Kirkwood and Sterne, 2003).  
Humoral and cellular immunity, determined as titres of anti-PCV2 antibodies and frequencies 
of IFN-γ SC respectively and also quantitative data of cytokine gene expression were 
statistically evaluated by using ANOVA (analysis of variance) and Dunnett’s test in order to 
highlight differences between treatment groups and changes over time within the same group 
throughout the experiment. The significance level was set to p<0.05. 
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3.2. Results 
 
3.2.1. Morbidity and mortality evaluation: reduction in PCV2-vaccinated animals 
In both herds, clinical signs potentially compatible with PMWS were mainly observed during 
the fourth and fifth month after vaccination (weeks 16-23 PV).  
Morbidity was quantified by recording the number of individual antimicrobial treatments 
(injections) during the duration of the experiment. Unvaccinated animals received more 
injections than PCV2-vaccinated throughout the study (Fig. 5); according to the statistical 
analysis using a Poisson model, the differences between groups were significant (P < 0.0001). 
Specifically, animals belonging to group A (placebo/ controls) are expected to receive 30% 
more injections as compared to vaccinated pigs [95% confidence interval (CI95%): 16-50%]. 
Pathologic and virologic investigations were carried out to categorise dead pigs, animals 
needing euthanasia, and runt non-marketable pigs (lost pigs) as PMWS or non-PMWS, using 
the recognised diagnostic criteria. Before the onset of viremia, the mortality rates in both 
groups were comparable and all dead animals were not affected by PMWS. 
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Figure 5. Course of morbidity (injections/pigs) in placebo/control (group A) and PCV2-vaccinated 
(Group B) animals (Poisson model; P < 0.0001). 
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At 15-16 weeks of age and onward in both herds, mortality was associated with PCR 
positivity to PCV2 and with macroscopic and microscopic lesions referred as PMWS using 
the pathologic criteria. The details of the occurrence of mortality categorised as PMWS or 
non-PMWS on a weekly basis at both farms are shown in figure 6.  
 
 
 
Figure 6. Losses due to PMWS and non-PMWS in PCV2-vaccinated and placebo/control pigs of farm 
1 (top) and farm 2 (bottom). Legend: PMWS C: control pigs diagnosed as PMWS-affected;                    
NON PMWS C: control pigs not affected by PMWS; PMWS V: vaccinated pigs diagnosed as                     
PMWS-affected; NON PMWS V: vaccinated pigs not affected by PMWS. 
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After the onset of PCV2 viremia, pigs belonging to the group of animals that had to be 
euthanised or removed because they were runts, were removed from the study because of 
wasting (15 vs. 0 pigs; placebo/control vs. vaccinated), growth retardation (12 vs. 3 pigs, 
respectively), locomotory disorders (4 vs. 5 pigs, respectively), and intestinal torsions (1 vs. 2, 
respectively).  
Before the onset of viremia, total losses were 7.3% and 7.8% and after PCV2 viremia 9.02% 
and 0.2%, respectively in the placebo/control and vaccinated groups. Overall, considering 
both herds for the study duration, total losses (dead, euthanised, and runts) were 16.03% and 
8.0% in the placebo/control and vaccinated groups, respectively. The estimated hazard ratio 
for losses related to PMWS in group B (vaccinated animals) compared to group A 
(placebo/control) was 0.082 (CI95%: 0.030-0.229; P< 0.0001; Fig. 7). 
 
 
 
Figure 7. Probability of a pig in the placebo/control (A) and PCV2-vaccinated (B) groups to be lost 
because of PCVD and other causes according to the estimated hazard risk over time, in both farms. 
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Under the conditions of this study, according to a stratified Cox proportional hazard model 
accounting for the non independence of repeated measurement of the same subject and the 
effect of the sow (litter effect) and for the competing risks of dying from other causes, the 
probability of a pig vaccinated with a single dose of the test vaccine at 3 weeks of age 
suffering from PCVD/PMWS was 12 times less than an unvaccinated control pig. The overall 
efficacy of the vaccine administered, expressed as preventive fraction was 0.918                        
(CI95%: 0.771-0.970). The preventive fraction represents and provides the proportion of cases 
that can be prevented by vaccination compared to the unvaccinated population.  
 
 
3.2.2. ADWG and carcass weight at slaughterhouse  
The ADWG is a parameter used to measure the effect of PMWS either in acute or in 
subclinical cases.  
Table 4 shows the ADWG in vaccinated and placebo/control animals for the intervals among 
the three different weighing time points. Significant differences in the ADWG between the 
treatment groups were not observed during the first time period (3-12 weeks of age), whereas 
they were observed during the subsequent time period (12-26 weeks), when the vaccinated 
animals had 70 g/day higher weight gain than placebo/control animals (P< 0.001).  
Moreover, the proportion of animals whose body weight was at least 25% lower than the 
mean body weight of the respective treatment group at 26 weeks of age was 6.5% and 2.6% in 
placebo/control and vaccinated groups, respectively. Carcass weights in pigs from farm 2 
were recorded at the slaughterhouse, as shown in Table 4. In vaccinated animals, the average 
carcass weight was 4.5 kg higher than in placebo/controls (P < 0.012). 
 
Table 4. ADWG in PCV2-vaccinated (group B) and placebo/control (group A) for two intervals 
between three different weighing time points during two study periods and carcass weight at slaughter. 
 
ADG (g) A B Diff. P value 
3-12 weeks of age 481 478 +3 > 0.05 
12-26 weeks of age 811 881 -70 < 0.001 
CARCASS (kg) * 140.5 145.0 +4.5 < 0.012 
 
            *carcass weight with head left on 
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3.2.3. PCV2 genome detection and viremia calculation 
The course of PCV2 viremia at both farms is shown in figure 8. 
A rapid onset of viremia was observed at 16-17 weeks of age at both farms. 
In placebo/control animals of farm 1, peak levels of 95-100% of PCR-positive blood samples 
were reached when animals were 20-22 weeks old. A decline of PCR positivity was detected 
at 26 weeks. The majority of samples with high viral loads (>106 DNA copies/ml of serum) 
were observed at 19-22 weeks of age (Fig. 8a), and 70% of the animals had at least one blood 
sample with a viral load >107 DNA copies/ml.  
Contrarily, in the vaccinated group, the proportion of viremic pigs was significantly lower 
compared to the placebo/control group; between weeks 19 and 22 of age, 40% of the animals 
were viremic, with a viral load never >106 DNA copies/ml serum (Fig. 8a).  
At farm 2, the peak of viremia was observed at 18-20 weeks of age with 95% PCR-positive 
pigs; pigs with a high viral load ranged from 55% to 60% (Fig. 8b). A viral burden >107 DNA 
copies/ml was detected in 42% of blood samples from the controls. 
In the vaccinated group only one blood sample was PCR positive at 18 weeks of age, with a 
low viral burden (<106 DNA copies/ml; Fig. 8b). 
 
 
(a) 
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Figure 8. Course of viremia over time in placebo/control and PCV2-vaccinated pigs of farm 1 (a) and 
farm 2 (b). Data are expressed as number of PCV2 DNA copies/ml of serum. 
 
 
The present data clearly indicate that vaccination against PCV2 induced a statistically 
significant reduction of the viral load in the blood and of the proportion of viremic animals for 
both farms in this study (P < 0.001). 
 
 
3.2.4. Serology 
 
3.2.4.1. Production of specific antibodies following PCV2 vaccination and infection 
The course of serology for PCV2 at both farms is shown in figure 9.  
At inclusion (vaccination day), due to residual maternally derived antibodies (MDA), pigs of 
both placebo/control and PCV2-vaccinated groups showed comparable levels of ELISA 
antibodies (5.95 and 6.69 log2, respectively). The difference was not statistically significant.  
After vaccination, PCV2-specific antibody titres progressively declined in placebo/control 
animals, whereas a significant increase was observed in vaccinated pigs. Starting at 2 weeks 
PV, the differences between the two groups were statistically significant. Animals in the 
vaccinated groups showed a continuous increase of total antibody titres, reaching a peak of 
ELISA antibodies at 6-9 weeks PV, with an average geometric mean ranging from                        
(b) 
Chapter 3                                                                                                                 Experimental Study 
47 
12 to 13 log2. From this time point on, the levels of total antibodies in vaccinated groups 
slightly decreased even if never below a geometric mean of 6 log2.  
At the last time point of blood sampling before the onset of viremia, the placebo/control 
animals from farm 1 showed a geometric mean of total antibodies under the cut-off for 
positivity (set at 2 log2), while this parameter was a little over the limit (3.4 log2) in 
placebo/control pigs of farm 2. In approximately 10% of the sampled population, the antibody 
titres at inclusion were higher than 8 log2. In vaccinated animals these titres showed neither an 
increase as a consequence of vaccination nor a decline but maintained a steady course over 
time.  
In the placebo/control group, the decline of maternally derived antibodies in animals with a 
titre higher than 8 log2 reached low levels within 10 weeks approximately (data not shown). 
At both farms, after the onset of PCV2 viremia, seroconversion occurred within 2-3 weeks in 
placebo/control or vaccinated groups so that at 20-22 weeks of age the antibody levels in both 
groups were comparable (11-12 log2). At 26 and 35 weeks of age, vaccinated animals had 
lower geometric mean antibody titres than that in placebo/control pigs because of a 
continuing increase of antibodies in the latter group of animals. At the last sampling time 
point of this trial (35 weeks of age), total ELISA antibodies were above the titre of 10 log2            
in both treatment groups. 
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Figure 9. Course of the serologic response to PCV2 (anti-PCV2 antibodies) at farm 1 and farm 2 from 
inclusion (3 weeks of age) to the end of the trial (data are expressed as log2 of the geometric mean 
titres, GMT). 
 
 
 
3.2.4.2. Antibody response to other infections 
Serologic investigations performed to monitor the most frequently occurring infections in the 
herds (PRRSV and M. hyopneumoniae) found that the prevalence of PRRSV infection was 
100% at 12 weeks of age in pigs from farm 1 concomitantly with M. hyopneumoniae 
seroconversion. For this latter pathogen, seroprevalence continued to increase in the 
subsequent period.  
At farm 2, at 12 weeks of age, pigs of both groups were positive (100%) for PRRSV and still 
negative for M. hyopneumoniae. Seroconversion to M. hyopneumoniae started to be detected 
after 15 weeks of age (data not shown). At both farms, low titres of antibodies at HI to            
Swine Influenza Virus were detected in some samples and were not informative. 
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3.2.5. Levels of IFN-γ secreting cells detected by ELISpot assay in response to PCV2-
vaccination and infection 
 
3.2.5.1. ELISpot assay: antigen recall with 0.1 MOI of PCV2 
After vaccination, PCV2-vaccinated animals showed an increased level of PCV2-specific 
IFN-γ SC at 2 weeks PV and reached a peak with a mean value of 120 IFN-γ SC/106 PBMC  
1 week later. The mean values remained the same until 9 weeks of age (Fig. 10).  
In the same period, at 2-3 weeks after vaccination, the number of animals with a progressively 
higher individual IFN-γ response increased (Tab. 5).  
In pigs from the placebo/control group the number of PCV2-specific IFN-γ SC remained at 
basal levels (<20 PCV2-specific IFN-γ SC) for the entire post-vaccination period (Fig. 10) 
and no significant individual differences were found (Fig. 10). After the occurrence of the 
infection at 15-16 weeks of age, vaccinated animals showed an erratic course in the number of 
PCV2-specific IFN-γ SC with moderate individual increases ranging from 40 to 60 IFN-γ-SC 
on average (Fig. 10).  
 
 
Figure 10. IFN-γ PCV2-specific SC levels in placebo/control and PCV2-vaccinated animals after 
vaccination at 3 weeks of age (a = placebo/control; b = vaccinated) and after natural exposure to PCV2 
(c = placebo/control; d = vaccinated). 
 
 
weeks of age 
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Oppositely, in unvaccinated pigs, IFN-γ SC showed a significant increase (P < 0.01)                     
with mean values of 196 and 244 IFN-γ SC at 19 and 20 weeks of age, respectively.                   
The mean values remained at high levels (140 IFN-γ SC) until 26 weeks of age (Fig. 10).  
 
The ELISpot IFN-γ SC response after vaccination (PV period) and after exposure to PCV2 
natural infection (PE period) of a representative PCV2-vaccinated and an unvaccinated 
natural infected pig is shown in figure 11. 
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Figure 11. PCV2-specific IFN-γ ELISpot response of a representative PCV2-vaccinated and an 
unvaccinated pig in the post-vaccination (a) and in the post-exposure period (b). The number of spots 
corresponds to the number of IFN-γsecreting cells / 2x105 PBMC.  
 
 
It is worth noting that the IFN-γ-SC response was characterised by a high inter-individual 
variability, with some pigs showing a very high PCV2-specific secretion (high responders; 
Table 6). 
In order to better evaluate the ex vivo PCV2-specific responses within the same experimental 
group, ELISpot results related to farm 1 were also analysed by grouping animals in 
responsiveness categories. 
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As shown in Table 5, the PCV2-vaccinated group showed an increasing percentage of more 
highly responsive animals to the ex vivo recall PCV2 I12/11 strain overtime. In fact, after                   
5 weeks of age (2 weeks post-vaccination) 30-40% of vaccinated animals responded to the 
stimulus with more than 105 IFN-γ SC/106 PBMC, mounting responses categorised in this 
study as intermediate, high and very high. At 7 and 8 weeks of age, 10% of vaccinated pigs 
showed a higher response to more than 405 IFN-γ SC/106 PBMC. On the contrary, 
unvaccinated animals showed absent or minimal responses, between 0 and 40 SC/106 PBMC, 
having however the majority of pigs showing a response between 0 and 20 SC/106 PBMC to 
the ex vivo stimulation at each experimental point.  
During the post-exposure period (Table 6), the majority of vaccinated pigs showed a cellular 
response lower than 100 SC/106 PBMC; only 10% and 20% of animals showed an 
intermediate response at 17 and 21 weeks of age respectively.  
The animals from the placebo/control group responded, instead, increasing the IFN-γ SC 
frequency. In this group, the highest numbers of IFN-γ SC were reached between                        
19 and 21 weeks of age, with a maximum (20% of pigs showing more than 405 IFN-γ SC/106 
PBMC) at 20 weeks.  
 
Table 5. IFN-γ responsiveness categories in PCV2-vaccinated and placebo/control pigs in the post-
vaccination period. Values are reported as percentage of animals within the group. SC: secreting cells. 
 
Responsiveness categories (IFN-γ SC / 106 PBMC)  
PCV2-VACCINATED 
 
0-40 45-100 105-200 205-400 ≥ 405 
weeks of age (PV period) no-poor low intermediate high  very high 
3 100 0 0 0 0 
4 90 10 0 0 0 
5 40 20 30 10 0 
6 30 30 20 20 0 
7 40 20 30 0 10 
9 50 20 10 10 10 
 
     
0-40      
PLACEBO/CONTROL 
 
0-40 45-100 105-200 205-400 ≥ 405 
weeks of age (PV period) no-poor low intermediate high very high 
3 100 0 0 0 0 
4 100 0 0 0 0 
5 100 0 0 0 0 
6 100 0 0 0 0 
7 100 0 0 0 0 
9 100 0 0 0 0 
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Table 6. IFN-γ responsiveness categories in PCV2-vaccinated and placebo/control pigs in the post-
exposure period. Values are reported as percentage of animals within the group. SC: secreting cells. 
 
Responsiveness categories (IFN-γ SC / 106 PBMC)  
PCV2-VACCINATED 
 
 
0-40 45-100 105-200 205-400 ≥ 405 
weeks of age (PE period) no-poor low intermediate high  very high 
15 50 50 0 0 0 
16 60 40 0 0 0 
17 40 50 10 0 0 
18 70 30 0 0 0 
19 10 90 0 0 0 
20 90 10 0 0 0 
22 40 40 20 0 0 
26 60 40 0 0 0 
 
     
 
PLACEBO/CONTROL 
 
 
0-40 45-100 105-200 205-400 ≥ 405 
weeks of age (PE period) no-poor low intermediate high very high 
15 75 25 0 0 0 
16 80 20 0 0 0 
17 45 55 0 0 0 
18 50 40 10 0 0 
19 30 40 20 0 10 
20 35 10 20 15 20 
22 10 35 45 5 5 
26 5 45 20 30 0 
 
 
 
3.2.5.2. ELISpot assay: comparison of three different PCV2-specific stimulations  
In order to evaluate the influence of the amount of viral antigen (whole PCV2) used for the      
ex vivo antigenic recall on the identification and extent of the PCV2-specific IFN-γ SC 
response detected by the ELISpot assays, PBMC were stimulated with also 0.05 and 0.25 
MOI, in addition to 0.1 MOI as reported above.  
During the post-vaccination period, upon re-stimulation with each virus-to-cell ratio (MOI) 
tested, vaccinated pigs showed a significant response as IFN-γ SC starting from 2 weeks PV 
(Fig. 12). Contrarily, unvaccinated pigs did not show any significant response at any MOI 
throughout the PV period. The course of the IFN-γ secreting cells over time detectable after 
recall with 0.1 MOI of virus was confirmed in both experimental groups also using a lower 
(0.05 MOI) and a higher (0.25 MOI) amount of virus. Specifically, re-stimulation with               
0.25 MOI showed a peak response at 3 weeks PV (6 weeks of age) with the highest mean 
value of about 200 IFN-γ SC/106 PBMC. The cellular response in vaccinated animals was 
clearly influenced by the ex vivo antigenic stimulus in a dose-dependent manner.  
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Figure 12. PCV2-specific IFN-γ secreting cell responses of PCV2-vaccinated (PCV2-vac) and 
placebo/control (Plac/Ctrl) pigs stimulated with 0.05, 0.1 and 0.25 MOI during the post-vaccination 
(PV) period. Values are expressed as mean values.  
 
 
In the post-exposure period, the ELISpot results obtained with 0.1 MOI of virus were 
confirmed both at 0.05 and 0.25 MOI (Fig. 13). In fact, at each MOI used for the ex vivo              
re-stimulation, the placebo/control pigs showed higher frequencies of IFN-γ SC than the 
PCV2-vaccinated animals between 19 and 26 weeks of age. The most intense cellular 
response were detected at 19-20 weeks of age.  
Despite high individual variability was observed, the response detected only in the 
unvaccinated group appeared to be influenced by the amount of virus antigen used for                      
re-stimulation in a dose-dependent manner. Vaccinated animals showed a lower and more 
steady (not influenced by the antigen amount) response throughout the PE period. 
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Figure 13. Comparison of the frequencies of PCV2-specific IFN-γ secreting cells of PCV2-vaccinated 
(PCV2-vac) and placebo/control (Plac/Ctrl) pigs detected upon ex vivo re-stimulated with 0.05, 0.1              
or 0.25 MOI during the post-exposure (PE) period. Values are expressed as mean values. 
 
 
 
3.2.6. Cytokine mRNA expression 
The evaluation of pro-inflammatory and immune cytokine mRNA expression was carried out 
in PBMC from PCV2-vaccinated pigs and from unvaccinated pigs that showed or did not 
show PCV2 infection and the related disease. During infection, some statistically significant 
changes of the investigated cytokines were observed between groups. The mRNA cytokine 
expression was studied by using the RT-qPCR technique. The performed PCR reactions 
provided target-specific amplification in all samples with minimal, not significant or absent 
signals related to primer dimer amplification. Each single amplification experiment was 
evaluated by monitoring amplification curves (Fig. 14) and melting profiles to exclude               
non-specific amplification (e.g. contamination by genomic DNA) or primer dimer negative 
effects (Fig. 15). 
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Figure 14. Representative amplification curves of GAPDH, IL-8 and IL-1β obtained by using        
Fast SYBR® Green Master Mix (Applied Biosystems). Target genes = IL-8 and IL-1β;               
housekeeping gene = GAPDH. Pink curves correspond to no template control (NTC) fluorescence 
signals. 
 
 
 
 
Figure 15. Representative melting curves of GAPDH, IL-8 and IL-1β obtained by using                    
Fast SYBR® Green Master Mix (Applied Biosystems). Target genes = IL-8 and IL-1β;               
housekeeping gene = GAPDH. Pink curves correspond to no template control (NTC). 
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IL-8 mRNA expression levels showed significantly higher values in vaccinated animals than 
in the two unvaccinated groups at 22 weeks of age (p<0.05; Fig. 16). TNF-α expression 
increased in vaccinated animals at 19 and especially at 22 weeks of age (p<0.05; Fig. 17). 
Conversely, for IL-1β, the comparison of mRNA expression levels between the three groups 
did not show any statistically significant difference at any of the considered time points              
(Fig. 18). 
 
             
Figure 16. Relative mRNA expression of the pro-inflammatory cytokine IL-8 in PBMC of vaccinated 
(PCV2-vac) and unvaccinated non-PMWS-affected (Ctrl) or PMWS-affected (Ctrl-PMWS+) pigs 
exposed to PCV2 natural infection. Data, obtained by RT-qPCR (2-∆∆Ct method), are shown as               
mean values ± standard deviation. (*): p<0.05. 
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Figure 17. Relative mRNA expression of the pro-inflammatory cytokine TNF-α in PBMC of 
vaccinated (PCV2-vac) and unvaccinated non-PMWS-affected (Ctrl) or PMWS-affected                          
(Ctrl-PMWS+) pigs exposed to PCV2 natural infection. Data, obtained by RT-qPCR (2-∆∆Ct method), 
are shown as mean values ± standard deviation. (*): p<0.05. 
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Figure 18. Relative mRNA expression of the pro-inflammatory cytokine IL-1β in PBMC of 
vaccinated (PCV2-vac) and unvaccinated non-PMWS-affected (Ctrl) or PMWS-affected                          
(Ctrl-PMWS+) pigs exposed to PCV2 natural infection. Data, obtained by RT-qPCR (2-∆∆Ct method), 
are shown as mean values ± standard deviation. (*): p<0.05. 
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The expression of IFN-γ was statistically higher in vaccinated animals both at 19 and                    
22 weeks of age compared to the Ctrl-PMWS+ and Ctrl groups (Fig.19). Interestingly,                      
a progressive decrease of IFN-γ expression was found in all experimental groups 
concomitantly with PCV2 infection. 
At 19 weeks of age, Ctrl-PMWS+ animals had a significantly higher level of IL-10                   
(p<0.05, Fig. 20) than the other two groups while no relevant differences were found between 
groups at the end of the study.  
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Figure 19. Relative mRNA expression of the pro-immune cytokine IFN-γ in PBMC of vaccinated 
(PCV2-vac) and unvaccinated non-PMWS-affected (Ctrl) or PMWS-affected (Ctrl-PMWS+) pigs 
exposed to PCV2 natural infection. Data, obtained by RT-qPCR (2-∆∆Ct method), are shown as                
mean values ± standard deviation. (*): p<0.05. 
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Figure 20. Relative mRNA expression of the regulatory cytokine IL-10 in PBMC of vaccinated 
(PCV2-vac) and unvaccinated non-PMWS-affected (Ctrl) or PMWS-affected (Ctrl-PMWS+) pigs 
exposed to PCV2 natural infection. Data, obtained by RT-qPCR (2-∆∆Ct method), are shown as                 
mean values ± standard deviation. (*): p<0.05. 
 
 
 
3.2.6.2. Course of viremia over time 
Serum samples of vaccinated and unvaccinated Ctrl or Ctrl-PMWS+ pigs were analysed by 
real-time qPCR to detect PCV2 DNA. The course of PCV2 viremia is shown in figure 21.  
The onset of viremia was observed in both groups after 16 weeks of age; the highest levels of 
PCR-positive animals and viral load were reached when animals were 19 weeks old whereas a 
decrease was found at 22 weeks of age.  
The mean values of viremia in vaccinated pigs (Fig. 21) remained significantly lower 
(p<0.01) than the values of the control groups, both at 19 and 22 weeks of age. Moreover, in 
vaccinated pigs, a small percentage of animals (20% and 30% at 19 and 22 weeks of age, 
respectively) resulted viremic and the viral burden always remained <106 DNA copies/ml of 
serum (Fig. 22a).  
In the control PMWS+ group, the proportion of viremic animals with high viral load                   
(≥106 DNA copies/ml) was 100% at 19 weeks, and 33.3% became low viremic                   
(<106 DNA copies/ml) at 22 weeks of age (Fig. 22c).  
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In the Ctrl group, the percentage of viremic pigs increased from 19 to 22 weeks of age, 
showing 43.7% and 62.5% of animals with a high viral burden respectively (Fig. 22b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Course of viremia over time vaccinated (PCV2-vac) and unvaccinated PMWS-free (Ctrl) 
or PMWS-affected (Ctrl-PMWS+) pigs exposed to PCV2 natural infection. Data are expressed as 
mean values ± standard deviation of the number of PCV2 DNA copies/ml of serum.                           
Different superscript letters indicate a statistical difference (p < 0.05). 
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Figure 22. Percentage of PCV2-specific viremic pigs in vaccinated (PCV2-vac) (a) and unvaccinated 
PMWS-free (Ctrl) (b) or PMWS-affected (Ctrl-PMWS+) animals (c). Data are calculated before the 
onset (16 weeks of age) and during the outcome of the disease (19 and 22 weeks of age). 
(c) 
(b) 
(a) 
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3.2.6.3. Association between cytokine mRNA expression and viral load in the blood 
Pro-inflammatory and immune cytokine mRNA expression was also evaluated in relation to 
the viremia burden. 
According to the amount of PCV2 in serum, three different subgroups were considered in 
order to have further information about the cytokine kinetics both in vaccinated and 
unvaccinated PCV2 groups as previoulsy stated (PCV2-vac, Ctrl-PMWS+ and Ctrl):                   
non-viremic pigs (NV), pigs with viremia <106 PCV2 DNA copies/ml of serum (V<106 ),  
and pigs with viremia ≥106 PCV2 DNA copies/ml of serum (V≥106).  
 
Table 7 shows the modulation of cytokine levels observed between all subgroups of each 
experimental group (PCV2-vac, Ctrl, Ctrl-PMWS+) over time. 
Comparing IFN-γ expression in relation to the extent of viremia between groups                        
(PCV2-vac; Ctrl-PMWS+ and Ctrl) over time (Table 7), despite a decreasing trend of this 
cytokine from 16 to 22 weeks of age in all considered groups, in PCV2-vac animals IFN-γ did 
not show differences between the newly constituted subgroups both at 19 and 22 weeks of 
age. Nevertheless, these animals maintained higher expression levels compared to the 
subgroups in Ctrl and Ctrl-PMWS+ animals. Particularly, PCV2-vac animals even with low 
viremia (V<106) had higher IFN-γ expression than highly viremic pigs in both Ctrl groups at 
22 weeks of age (p<0.05). 
IL-10 mRNA expression appeared to increase in relation to the occurrence of infection and in 
relation to the extent of viremia (Table 7); particularly, highly viremic (V≥106) animals of the 
Ctrl-PMWS+ group showed an early increase (19 weeks of age) of this cytokine compared to 
PCV2-vac animals and Ctrl groups.  
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Table 7. Levels of immune cytokine mRNA expression in PBMC of vaccinated (PCV2-vac)                      
and unvaccinated PMWS-free (Ctrl) or PMWS-affected (Ctrl-PMWS) pigs exposed to PCV2 natural 
infection in the post-exposure period.  
 
weeks of age Cytokines Groups Subgroups 
of viremia           16                        19                     22 
NV 2.1± 0.9a 1.1 ± 0.4b 0.7 ± 0.4b 
V<10^6 - 1.0 ± 0.9a 1.0 ± 0.8a 
 
PCV2-Vac  
V≥10^6 - - - 
NV 1.4 ± 0.7a 0.4 ± 0.2b - 
V<10^6 - 1.0 0.4 ± 0.2b 
 
Ctrl 
V≥10^6 - 0.6 ± 0.2a 0.3 ± 0.1a 
NV 1.2 ± 0.7  - - 
V<10^6 - - 0.4 
 
 
 
IFN-γ 
 
Ctrl-PMWS+ 
V≥10^6 - 0.6 ± 0.5 0.4 ± 0.1a 
NV 1.3 ± 0.5a 1.0 ± 0.6a 1.4 ± 0.5a 
V<10^6 - 0.6 ± 0.1a 2.5 ± 0.7b 
 
PCV2-Vac 
V≥10^6 - - - 
NV 1.5 ± 0.6a 0.8 ± 0.5b - 
V<10^6 - 0.8 2.1 ± 0.4b 
 
Ctrl 
V≥10^6 - 0.7 ± 0.4a 2.1 ± 0.6b 
NV 1.6 ± 1.1 - - 
V<10^6 - - 1.8 
 
 
 
IL-10 
 
Ctrl-PMWS+ 
V≥10^6 - 2.4 ± 2.3a 1.6 ± 0.7a 
 
Values are expressed as mean ± S.D. of the cytokine mRNA expression (arbitrary units were 
calculated with the 2-∆∆CT method). ( - ) indicates no value of gene expression since no pigs belonged 
to the specific subgroup of viremia at that time point. Different superscript letters indicate a statistical 
difference (p < 0.05) between time points within the same subgroups of viremia. 
 
 
As shown in Table 8, the expression levels of IL-8 and IL-1β increased between 19 and 22 
weeks of age in each subgroup of viremia of both PCV2-vac and Ctrl animals but not in the 
Ctrl-PMWS+ group. 
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Table 8. Levels of pro-inflammatory cytokine mRNA expression in PBMC of vaccinated (PCV2-vac) 
and unvaccinated PMWS-free (Ctrl) or PMWS-affected (Ctrl-PMWS) pigs exposed to PCV2 natural 
infection in the post-exposure period.  
 
weeks of age Cytokines Groups Subgroups 
of viremia 16                          19                      22 
NV 2.8 ± 2.0a  5.5 ± 2.9a  18.9 ± 4.0b 
V<10^6 - 1.0 ± 1.1a 15.7 ± 4.8b 
 
PCV2-Vac 
V≥10^6 - - - 
NV 3.7 ± 3.0a  3.7 ± 2.6a - 
V<10^6 - 9.7 12.7 ± 5.9a 
 
Ctrl 
V≥10^6 - 1.3 ± 0.6a 9.9 ± 4.0b 
NV 1.6 ± 0.4a - - 
V<10^6 - - 8.7 
 
 
 
 
IL-8 
 
Ctrl-PMWS+ 
V≥10^6 - 6.3 ± 6.2a 7.2 ± 2.7a 
NV 1.9 ± 0.6a 1.2 ± 0.7a  1.9 ± 0.8a  
V<10^6 - 0.5 ± 0.1a  2.2 ± 0.9a  
 
PCV2-Vac 
V≥10^6 - - - 
NV 1.6 ± 0.5a 1.0 ± 0.7a - 
V<10^6 - 0.7 1.3 ± 1.1a 
 
Ctrl 
V≥10^6 - 0.5 ± 0.1a 1.0 ± 0.5a 
NV 1.3 ± 0.4a - - 
V<10^6 - - 1.8 
 
 
 
 
TNF-α 
 
Ctrl-PMWS+ 
V≥10^6 - 0.8 ± 0.4a 1.0 ± 0.2a 
NV 1.6 ± 0.9a 1,6 ± 1.1a 5.7 ± 2.9b 
V<10^6 - 0.4 ± 0.5a 4.2 ± 0.5b 
 
PCV2-Vac 
V≥10^6 - - - 
NV 2.3 ± 1.5a 2.5 ± 1.3a - 
V<10^6 - 1.3 6.6 ± 2.4a 
 
Ctrl 
V>10^6 - 0.6 ± 0.5a 3.4 ± 1.5b 
NV 0.9 ± 0.5a - - 
V<10^6 - - 0.7 
 
 
 
 
IL-1β 
 
Ctrl-PMWS+ 
V>10^6 - 2.7 ± 2a 3.6 ± 0.4b 
 
Values are expressed as mean ± S.D. of the cytokine mRNA expression (arbitrary units were 
calculated with the 2-∆∆Ct method). ( - ) indicates no value of gene expression since no pigs belonged 
to the specific subgroup of viremia at that time point. Different superscript letters indicate a statistical 
difference (p < 0.05) between time points within the same subgroups of viremia. 
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In particular, between 19 and 22 weeks, a statistically significant higher levels of IL-8 were 
detected in non-viremic (NV) PCV2-vaccinated compared to highly viremic (V≥106) control 
pigs and control PMWS+; in the same period, and particularly at 22 weeks of age, all 
subgroups of PCV2 vaccinated pigs showed higher levels of IL-1β compared to the highly 
viremic (V≥106) pigs of the Ctrl groups, TNF-α showed a similar trend to increase between 19 
and 22 weeks of age in PCV2 vaccinated group in respect to control viremic pigs but not if 
compared to PMWS pigs at 22 weeks. 
Overall, in Ctrl-PMWS+ pigs, lower IFN-γ at 19 weeks of age was associated with high IL-10 
and subsequently, at 22 weeks of age, is evident a reduction of pro-inflammatory cytokines, 
namely IL-8 and IL-1β (Table 7 and 8).  
Contrarily, the PCV2-vaccinated pigs, despite an increase of IL-10 from 19 to 22 weeks, 
showed higher levels of these pro-inflammatory cytokines at 22 weeks of age (Tables 7       
and 8). 
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The present Thesis reports a study performed to characterize the humoral and cell-mediated 
immune response upon PCV2 vaccination and natural infection, evaluating the efficacy of a 
one-dose of a commercial PCV2a sub-type based subunit vaccine containing the capsid 
protein expressed in a baculovirus system (Porcilis PCV®) in vaccinated and unvaccinated 
pigs subsequently exposed to PCV2 natural infection.  
The trial was performed at two large farms where the exposure of the animals to various 
pathogens such as PCV, PRRSV, M. hyopneumoniae, and commonly detected bacteria was 
the classical predisposing condition for PCVD (Kawashima et al., 2007). Under the 
conditions of this study, PCV2 infection was detected during the fifth month of age, a period 
in which also the onset of the clinical signs related to PCVD occurred in both herds.  
The test vaccine, administered intramuscularly with a single dose at 3 weeks of age, 
consistently reduced clinical signs attributed to PCVD as well as mortality, PCV2 viral load 
and viremia. Furthermore vaccinated animals showed a different response of                       
pro-inflammatory and immune cytokines upon PCV2-natural infection.  
Despite the vaccine used in this field trial and the schedule of administration had been tested 
under laboratory conditions (Fort et al., 2009a), no peer-reviewed paper has described its 
efficacy under field conditions.  
This study pointed out the effects of a PCV2 vaccine on farms with the presence of PCVD 
during the fattening period in animals aged 4-5 months, in line with the disease history in both 
farms. The effects of vaccination involved clinical signs and productivity (decreased numbers 
of pigs needing intramuscular therapy, improvement of ADWG, and decreased mortality) and 
PCV2 viral load in target organs of dead animals and in the blood of sampled pigs in amounts 
and duration of viremia.  
Serology demonstrated that PCV2 infection occurred in combination with other pathogens, 
namely, PRRSV and M. hyopneumoniae, in both herds. Morbidity was measured recording, 
throughout the study, the number of individual treatments in unvaccinated and vaccinated 
animals and was significantly higher in the placebo/control group. According to the statistical 
model applied (Poisson model), unvaccinated animals were expected to receive on average 
30% more injections than vaccinated pigs.  
The efficacy of the vaccine under investigation was also evaluated by the comparison of 
ADWG. Before the onset of PCV2 viremia and associated diseases (from 3 to 12 weeks of 
age) no differences in ADWG were recorded. Conversely, when PCV2 viremia and PCVD 
occurred (from 12 to 26 weeks of age), the ADWG in vaccinated pigs was 70 g/day higher 
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than in controls as a result of the protective effect induced by vaccination. This result is 
improved compared to evidences reported in previous studies (Fachinger et al., 2008; Horlen 
et al., 2008; Kixmoller et al.,2008; Segale´ s et al., 2009). At 26 weeks of age 6.5% and 2.6% 
of animals from placebo/control and vaccinated groups, respectively, had a body weight at 
least 25% lower than the mean body weight of the respective treatment group.  
The overall mortality at both farms was reduced by vaccination; the statistically significant 
differences were related to a decreased number of pigs suffering from PMWS and showing 
specific lesions in target tissues. In fact, PMWS was the cause of death only for 1 of 408 
vaccinated pigs. The results show that a pig vaccinated with a single dose of Porcilis PCV®           
at 3 weeks of age had a probability of dying from PMWS 12 times less than that of                         
an unvaccinated control pig.  
Furthermore, the similar ADWG and mortality rates in both treatment groups within the first 
9 weeks after vaccination indicate that the vaccine does not negatively influence the health 
status of the animals and suggests that the vaccine is well tolerated. All the improved 
parameters are associated with a significant reduction in the proportion of infected pigs and in 
the viral load in the blood. 
To categorise pigs as subclinically infected, suspected, and diseased for PCV2-associated 
diseases, was used a classification based on the amount of PCV2 load in the blood, namely 
<106, between 106 and 107, and >107 DNA copies/ml, respectively (Olvera et al., 2004; 
Opriessniget al., 2007). During the period of PCV2 infection that occurs between 16 and 26 
weeks of age, high viral loads in serum (>107 DNA copies/ml) were detected in a high 
number of placebo/control pigs, whereas in vaccinated pigs the duration of viremia and the 
viral load were markedly lower. In fact, in the placebo/control group the 70% and 42% of 
pigs, for farms 1 and 2 respectively, showed an amount of PCV2 in the blood ≥107 DNA 
copies/ml. Conversely, none of the vaccinated pigs had a viral load in the blood as high as this 
level; it always was <106 DNA copies/ml. The ability to diminish both the proportion of 
infected pigs as well as the viral load of infected animals is one of the better-documented 
feature of PCV2 piglet vaccination under field conditions (Fachinger et al., 2008;                      
Horlen et al., 2008; Kixmoller et al., 2008).  
The reduced number of PCV2-positive pigs and of the viral load in vaccinated pigs is 
associated with the improved ADWG and reduced mortality. qPCR can be performed on 
samples from live animals; for this reason it is the most practical tool to monitor the efficacy 
of a vaccine treatment (Segales et al., 2010).  
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Quantitative PCR analysis showed that all tested animals were PCV2 negative at the time of 
vaccination so that the antibody titres detected were most likely of maternal origin.  
However, a prompt seroconversion is induced by the use of this PCV2-specific vaccine on 
piglets, independently of the level of MDA when the titres of ELISA antibodies are below an 
observed threshold of 8 log2 (approximately 90% of vaccinated pigs). Over this level, 
observed in approximately 10% of the vaccinated population, the antibody titres showed 
neither an increase as a consequence of vaccination nor a decline, but maintained a steady 
course over time. Thus, at the time of infection (>16-17 weeks of age) all vaccinated pigs, 
independently from the level of antibodies at vaccination, were protected showing an ELISA 
titre >6 log2.  
Conversely, placebo/control pigs presented either MDA <8 log2 or high levels (>8 log2)                   
at inclusion, and showed a gradually declining course that reached low levels within a few 
weeks. The high proportion of viremic pigs (100% and 95%, respectively, from farms 1 and 
2) and the incidence of clinical signs and mortality supported that, during the late infection 
phase, none of the control animals was protected. 
Using the conditions of this study, we suggest that it is possible to set two different thresholds 
of ELISA antibodies. In pigs with titre of MDA is >8 log2 seroconversion to vaccination does 
not occur; however, when infection occurred, these animals resulted protected and showed 
ELISA titres >6 log2. Conversely, in controls, the highest titres of MDA decline similarly so 
that, at later exposure to PCV2, the ELISA titres are <6 log2 and the animals are completely 
susceptible to infection with a high viral load. 
These results confirm that high MDA titres do not interfere with the effect of a single dose of 
the vaccine under investigation (Fort et al., 2008, 2009b; Opriessnig et al., 2008b) and that the 
vaccine is suitable for immunization of seropositive piglets, conferring clinical and virologic 
protection even if infection occurs very late after vaccination (≥4-5 months).  
In contrast to the results reported by Kixmoller et al. (2008), the significant increase of 
ELISA antibody titres in vaccinated animals from 3 weeks PV allows the use of this serologic 
investigation, and particularly seroconversion at two subsequent sampling time points, as a 
reliable tool to evaluate vaccine compliance differentiating vaccinated and controls before 
infection. However, the very low number of vaccinated animals becoming infected does not 
allow to assess a correlation between ELISA titres and clinical and virological protection. It is 
important to point out that under the conditions of this study, PCVD lasted at least until 26 
weeks of age and accordingly, the high increase of weight gain in vaccinated animals 
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compared to placebo/controls indicates that: a) PCVD have devastating effects if they occur at 
late time points (which is more and more often the case under field conditions), b) passively 
acquired maternal derived antibodies are not protecting at this age, c) this vaccine provides a 
long lasting protective immunity. 
The protective immunity induced by commercial PCV2 vaccines has been already 
investigated in terms of development of an effective humoral response, whereas the role of 
cell-mediated immunity has not been yet clarified. Fort and co-workers demonstrated, in some 
laboratory studies (2008, 2009b), that during the course of PCV2 infection pigs develop             
cell-mediated immunity specific to the virus and suggested that the development of       
PCV2-specific IFN-γ SC might contribute together with neutralising antibodies to viral 
clearance. 
 
In the present Thesis, we described disease under field conditions where coinfections are 
present and investigated the cell-mediated immune response after PCV2 vaccination and 
subsequent infection. Under laboratory conditions, experimentally challenged pigs do not 
show the specific PCV2-associated diseases, whereas under field conditions coinfections as 
well as other intrinsic or extrinsic factors exacerbate the disease.  
In this study the cell-mediated immunity specific for PCV2 vaccination/infection was 
determined as PCV2 specific IFN-γ Secereting Cells (SC) by means ELISpot assay.  
ELISpot assays detect a significant increase of the frequency of IFN-γ SC already at 2 weeks 
after vaccination, demonstrating that a single dose of the PCV2 Cap-based vaccine induces a 
virus-specific cell-mediated immune response.  
This evidence also suggests that cell-mediated responses play an important role in       
vaccine-induced protection, since the protective effect of PCV2 antibodies is titre dependent 
and the induction of a humoral response alone might not assure full protection against PCV2 
infection (Blanchard et al., 2003; Opriessnig et al., 2009; Fort et al.,2009b). 
A marked increase of IFN-γ SC was shown by control pigs after the onset of infection, and at 
the end of the observation period, their high levels of IFN-γ SC were also associated with a 
reduction of viremia. This demonstrates that cell-mediated responses is involved in the 
adaptive immunity that pigs develop over the course of the spontaneous PCV2 infection.  
According to Fort et al. (2009b), our result suggest that the IFN-γ SC response may be related 
to viral replication. Thus, in vaccinated pigs, as a consequence of the primary activation by 
vaccination, the number of these cells was rather low or at residual levels (ranging from                   
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40 to 60 IFN-γ SC/106 PBMC on average) and the PCV2 viral load remained low or absent 
overtime.  
Conversely, controls pigs had a higher frequency of IFN-γ SC, concomitantly with the 
increase of PCV2 antibodies and the exhibition of high levels of viremia and disease 
consistent with PCV2 replication. During the post-exposure period, the animals of the 
placebo/control group that showed the highest numbers of IFN-γ secreting cells (≥405 IFN-γ 
SC/ 106 PBMC at 20 weeks of age) were the ones that showed the highest levels of viremia.  
This association was observed in the majority of unvaccinated animals; an exception was 
shown by unvaccinated animals that died in which the constantly low levels of IFN-γ SC 
testify that the cell-mediated response was not efficiently triggered by antigen recognition and 
PCV2 replication (together with secondary co-infections) was not efficiently counteracted by 
the IFN-γ response.  
Contrarily, vaccinated pigs presented low levels of IFN-γ SC paralleled by absent or low 
viremia; these results suggest that the IFN-γ SC responses of these animals may act more 
efficiently and/or other efficient immune mechanisms, including virus-neutralizing antibodies, 
fast counteract virus spread before the need of further clonal proliferation of virus-specific 
IFN-γ secreting memory cells. 
The observed high response in controls with high viral load can be explained by the fact that 
the IFN-γ SC response develops against both Cap and Rep proteins, in fact, the intensity of 
the generated response differs using either the Cap protein or the whole PCV2 as ex vivo 
stimulus. The stimulation of PBMC with the whole virus can induce higher IFN-γ responses 
than with the Cap protein, suggesting that infected animals in which PCV2 is replicating 
might respond strongly to other viral components different from the Cap protein (Fort et al., 
2009a). It is worth noting that the cellular responses detected by using the ELISpot assay 
proved to be increased by using increasing amounts of virus for the ex vivo stimulation.  
Under the conditions of the present study, we cannot exclude that the interaction of PCV2 and 
the adaptive immunity might be modulated by coinfections, with effects on viral replication 
and load in vivo and on the onset of the clinical evidence in vivo.  
Based on these observations, even if further studies are required to elucidate the inner 
mechanisms used by cell-mediated immunity to complete viral clearance and its major 
antigenic target proteins, it seems that the development of the PCV2-specific cell-mediated 
response might help contrasting progression of PCV2 infection. 
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The knowledge on the activity of immune mediators such as cytokines and of lymphocyte cell 
subpopulations is the basis of vaccine strategies and protocols aimed at controlling the related 
diseases. The production of pro-inflammatory cytokines and the balance between pro-immune 
and regulatory cytokines play a pivotal role in stimulating the innate response and priming 
and substaining the adaptive immune response.  
This study investigated also the changes in the expression of pro-inflammatory (IL-8,                
TNF-α, IL-1β) and immune (IFN-γ, IL-10) cytokines in vaccinated and unvaccinated pigs, at 
specific time points of the post-exposure period. The obtained results were analysed in 
relation to the appearance of PMWS clinical signs and PCV2 specific viremia. 
As it is a field study and there are other infections, namely PRRS, it is worth to note that 
PRRV infection has occurred before the onset of PCV2 viremia as demonstrated by the high 
seroprevalence (100%) of PRRSV antibodies observed at 12 weeks of age and by the negative 
results obtained by PCR performed on the frozen samples at 16 and 19 weeks of age. 
Consequently, it’s rational to consider that between 19 and 22 weeks of age the probability to 
have a PRRSV infected animal is very reduced and that the major/unique infecting agent able 
to modulate the cytokine expression is PCV2. 
IL-8 is a chemokine involved in early inflammation and its primary function is the 
recruitment of inflammatory cells, especially neutrophils, by chemotaxis.  
At the early phase of infection, the mRNA expression of this pro-inflammatory cytokine was 
not significantly different between animals that subsequently developed PMWS                         
(Ctrl-PMWS+) and PCV2-vac or Ctrl group, whereas its up-regulation was observed in 
PCV2-vaccinated pigs later after PCV2 natural exposure (22 weeks of age). This could 
sustain a more efficient innate response against infection in immunized animals compared to 
controls: in fact, the IL-8 higher levels were associated with absent or minimal viral load. 
Conversely, in unvaccinated animals IL-8 expression showed a lower increase during 
infection, particularly in high viremic and diseased pigs. The values obtained in the late phase 
of infection (22 weeks of age) could parallel with the findings of lower IL-8 levels in 
lymphoid tissues at more advanced stages of the disease and increased lesions (Darwich et al., 
2003a, 2003b). 
TNF-α is a crucial pro-inflammatory cytokine that mediate local and systemic effetcs and play 
a crucial role in the innate immune response.  
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The level of TNF-α remained lower in the two unvaccinated groups (Ctrl and Ctrl-PMWS+) 
especially at 22 weeks, thus supporting a reduced efficiency of the inflammatory/innate 
immune response.  
With regards to the pro-inflammatory cytokine IL-1β, both the results in the vaccinated group 
over time and in animals categorized on the basis of PCV2 viremia burden, showed a trend to 
increase. As previously demonstrated by in vitro stimulation experiments (Darwich et al., 
2003a), the exposure to PCV2 can stimulate the secretion of IL-1β in vaccinated and healthy 
control pigs confirming their capability to react against PCV2 infection through effective 
inflammatory mechanisms.  
IFN-γ is a pro-immune cytokine mainly produced by Th1, cytotoxic T lymphocytes (CTL) 
and natural killer (NK) cells which plays a key role in the immune response against virus 
infections involving both innate and specific mechanisms; this cytokine sustains the activation 
of macrophages and stimulation of MHC type I and co-stimulatory molecule production in the 
differentiation of CD4+ naïve T helper cells into Th1 cells and also in the inhibition of                
Th2 cell proliferation. 
The evaluation of IFN-γ expression plays a very important role in the study of the immune 
response because it is responsible for the regulation and amplification of the antiviral 
response. The higher levels of IFN-γ in the vaccinated animals could support a higher 
immune reactivity to the infection able to rapidly and efficiently contrast viremia and the 
related occurrence of the disease. 
Indeed, the association between viral titre in serum samples and IFN-γ increase, as well as 
IFN-γ secreting cell frequency, underlined the relevance of cellular activation and antibody 
humoral reaction against PCV2 replication (Fort et al., 2009a, 2009b; Martelli et al., 2011; 
Meerts et al., 2005). Contrarely, reduced IFN-γ expression levels were found both in PBMC 
(Sipos et al., 2004; Shi et al., 2010; Darwich et al., 2003a) and in lymphoid tissues                
(Darwich et al., 2003b) of PMWS-affected animals.  
IL-10 is a regulatory cytokine, produced primarily by monocytes and to a lesser extent by 
lymphocytes, as immunosuppressive and anti-inflammatory molecule. It negatively inhibits 
macrophages and can inhibit the synthesis of pro-inflammatory cytokines such as IFN-γ,                
IL-2, TNF-α and GM-CSF (Meerts et al., 2005; Crisci et al., 2010). The antagonist immune 
cytokines, IFN-γ and IL-10, showed opposite levels in the early phase of PCV2 infection. 
In accordance with Darwich et al. (2008), control PMWS-affected animals (Ctrl-PMWS+) 
showed the highest IL-10 levels at the peak of viremia (19 weeks of age), likely supporting a 
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potential inibithory effect on the production of Th1 cytokines, such as IFN-γ                                    
(Shi et al., 2010). Indeed, the increased expression and production of IL-10 in tissues and 
PBMC were found both in the study of single infection and in PCV2-PRRSV coinfection 
cases (Doster et al., 2010; Shi et al., 2010; Darwich et al., 2003a). During PCV2 infection and 
the PCVD, IL-10 is mainly secreted by macrophage-monocyte and dendritic cell lineage but 
also by T cell clones, which have been impaired by a prolonged antigen stimulation; indeed 
PCV2 is able to stimulate the IL-10 release from PBMC and tissues (Darwich et al., 2003b; 
Kekarainen et al., 2008b; Crisci et al., 2010). 
In our study, Ctrl-PMWS+ animals showed significantly higher IL-10 expression levels 
compared to the other two groups at 19 weeks. On the contrary, in vaccinated-exposed 
animals, IFN-γ expression remained at higher levels at both post-exposure time points                  
(19 and 22 weeks of age), and this could testify a protective effect of vaccination. Because of 
the present data, is not possible to define a statistical correlation beteween IL-10 and IFN-γ 
changes, we cannot assume that IL-10 had a clear immunosuppressive role influencing the 
pathogenesis of PCV2 infection and the PMWS outcome.  
Anyway, taken together, all these information highlight that a different modulation of the 
cytokine profiles between animals vaccined with a PCV2 Cap protein-based vaccine and 
unvaccinated animals occurs. Particularly, in the case of these study, under natural conditions 
of PCV2 infection and PMWS outcome, cytokine modulation can indicate some 
immunoregulatory mechanism involving a reduction of early proinflammatory response as a 
condition that could influence the outcome of the PMWS disease.  
Besides, vaccinated pigs, in addition to low viremia burden and absence of PMWS disease, 
showed stronger cellular IFN-γ-related reactivity as well as an effective expression of                   
pro-inflammatory/innate cytokines (namely IL-8 and IL-1β) after the occurrence of the 
natural infection (week 19-20 to 22) contrarily to what is shown in PMWS-affected animals. 
 
In conclusion, the study reported in the present thesis demonstrates that the vaccination with 
a single dose of a PCV2 Cap vaccine against PCVD induces beneficial effect under field 
conditions.  
- The similarity between ADWG and mortality rates observed in both experimental 
groups within the first 9 weeks after vaccination, considered together with the absence 
of local reactions and the reduced number of injections in vaccinated animals as 
compared to placebo/controls in the same time period, support the hypothesis that the 
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vaccine does not negatively influence the health status of the animals and is well 
tolerated.  
- The vaccination reduces the mortality rate, morbidity, PCV2 viremia and viral load, 
and improves productive performances, namely, daily weight gain as well as carcass 
weight at the time of slaughter.  
- The immunogenicity of the tested vaccine is mainly determined by induction of either 
humoral (PCV2-specific total antibodies) or cellular immune response (PCV2-specific 
IFN-γ SC and some pro-inflammatory and immune cytokines patterns in PBMC) and 
results in virologic and clinical protection. 
Particularly, the evaluation of time-related expression changes of proinflammatory and 
immune cytokines showed some interesting results but their assessment as markers of 
infection and outcome of the PCV2 related diseases needs further studies.  
 
 
 
 
 
Marina Morganti 
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In 2009-2011, Dr. MARINA MORGANTI attended the doctoral course in                  
“Experimental and Comparative Immunology and Immunopathology” of University of Parma 
(Parma, Italy), performing research activities at the Unit of General Pathology and Veterinary 
Pathological Anatomy of the Department of Animal Health, Faculty of Veterinary Medicine, 
coordinated by Prof. Attilio Corradi.  
She worked as a Ph.D. student in the group headed by Prof. Paolo Borghetti, supervised by 
Dr. Luca Ferrari and Dr. Elena de Angelis, in collaboration with Prof. Paolo Martelli, 
Coordinator of the Unit of Internal Medicine, Department of Animal Health, especially with 
regards to the evaluation of vaccine efficacy and clinical signs upon PCV2 natural infection. 
 
In 2009 (first year of the Ph.D. course), Dr. Morganti dealt with the isolation, 
immunophenotyping and study of the cell-mediated immune response (after in vitro 
stimulation) of lymphocytes from peripheral blood of pigs PCV2-vaccinated.  
She also collaborated with the research group headed by Prof. Angelo Borghetti                             
(Unit of Molecular Pathology and Immunology, Department of Experimental Medicine, 
University of Parma), dealing with the following topics: 
- development of chitosan tubular prosthesis and evaluation of their potential application in 
replacement surgery of the biliary tract; 
- study of the pro-apoptotic activity of bisphosphonate drugs on cells of cholangiocarcinoma; 
- biological characterization of ozonated oils in models derived from epithelial and 
mesenchymal cells. 
 
In 2010 (second year), Dr. Morganti worked especially on the cell-mediated immune 
response in PCV2-vaccinated and unvaccinated pigs, subsequently exposed to PCV2 natural 
infection. The evaluation of pro-inflammatory and immune cytokine expression levels was 
performed in mononuclear cells isolated from peripheral blood (PBMC) by using quantitative 
RT-PCR. Intracellular staining coupled with flow cytometry was performed to determinate 
the fraction of IFN-γ-positive cells in PBMC, after in vitro stimulation with PCV2.  
 
From 01/08/2010 to 31/01/2011 Dr. Morganti attended the Laboratory of Immunology, 
Faculty of Veterinary Medicine of University of Ghent (Ghent, Belgium), coordinated by 
Prof. Eric Cox whose work has long been focused on the study of the immune response to 
infection by enterotoxigenic Escherichia coli F4+ (ETEC F4+) in swine. 
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During this period of internship she was mainly involved in: 
- Isolation of pigs immune cells from blood and jejunal lamina propria followed analysis of 
aminopeptidase-N (receptor for ETEC F4 fimbriae) expression and activation status of 
antigen-presenting cells by flow cytometry directly or after in vitro stimulation.  
- Study of the endocytosis mechanisms of aminopeptidase N in an experimental model using 
ST (Swine Testis) cells grown in trans-well systems by ELISA and immunocytochemistry. 
- Transfection experiments to obtain a porcine cell line stably expressing aminopeptidase-N     
to use as experimental model. 
 
In 2011 (third year) Dr. Marina Morganti worked on the following research projects: 
• Study of the humoral and cell-mediated immune response in pigs simultaneously 
vaccinated against PCV2 and PRRSV and subsequently exposed to natural infection by 
both viruses. Comparison of double vaccination with single vaccinations (PCV2 or 
PRRSV alone) and unvaccinated animals.  
- ELISPOT assays were performed to evaluate the number of virus-specific IFN-γ 
secreting cells in PBMC; 
- quantitative RT-PCR experiments were performed to study the expression levels of 
pro-inflammatory and immune cytokines such as TNF-α and IL-10, respectively. 
- ELISA were performed to evaluate seroconversion to PCV2 and PRRSV and the 
levels of virus-specific IgG and IgM antibodies over time.  
- Viremia burden was determined by quantitative real-time PCR in serum and fecal 
samples. 
• Study of the cell-mediated immune response in PCV2-vaccinated and unvaccinated pigs, 
subsequently exposed to PCV2 natural infection. The expression levels of several                    
pro-inflammatory and immune cytokines were evaluated by using quantitative RT-PCR; 
the number of PCV2-specific IFN-γ producing cells in PBMC was determined after                    
in vitro-ex vivo stimulation by intracellular staining and ELISpot assay.  
• Assessment of cytokine patterns in PBMC of pigs vaccinated and unvaccinated against 
PRRSV and subsequently exposed to natural infection by a heterologous strain, after                 
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in vitro stimulation with different PRRSV isolates. Following the in vitro stimulation, 
cytokine expression was assessed in PBMC by semi-quantitative RT-PCR and cytokine 
release was quantified by ELISA in the supernatants of cultured cells. The number of 
IFN-γ secreting cells in PBMC ex vivo re-stimulated with PRRSV strains was also 
measured. 
 
 
Congresses 
 
1) “Modulazione di citochine pro-infiammatorie e immunitarie in PBMC di suini vaccinati e 
non vaccinati esposti a infezione naturale da circovirus tipo 2 del suino (PCV2)”.              
Ferrari L., Morganti M., Borghetti P., De Angelis E., Martelli P. Proceedings of the 
Società Italiana di Patologia ed Allevamento dei Suini (SIPAS), XXXVII Annual Meeting 
– Piacenza, 24-25 March 2011, 266-276 (ISBN 978-88-903311-3-8). 
 
2) “Pro-inflammatory and immune cytokines in PBMC of vaccinated and unvaccinated pigs 
exposed to porcine circovirus type 2 (PCV2) natural infection”. Ferrari L., Morganti M., 
Borghetti P., De Angelis E., Martelli P. Proceedings of the 3rd European Symposium on 
Porcine Health Management (ESPHM) – Espoo, Finland, 25-27 May 2011, 21. 
 
3) “Evaluation of cytokines and immunomodulatory hormones in pigs vaccinated against 
PRRSV and naturally exposed to a heterologous field isolate”. Ferrari L., Borghetti P., 
Morganti M., Martelli P. International PRRS Symposium (IPRRS Symposium) – Chicago, 
USA, 2-3 December 2011, 31. 
 
4) “Immune reactivity is associated with clinical protection upon vaccination with a 
modified-live PRRSV-1 vaccine and subsequent exposure to natural infection by a field 
strain”. Ferrari L., Borghetti P., Morganti M., Martelli P. International PRRS Symposium 
(IPRRS Symposium) – Chicago, USA, 2-3 December 2011, 32. 
 
5) “Different cytokine patterns in ex vivo stimulated PBMC are related to the PRRSV 
isolate”. Ferrari L., Borghetti P., De Angelis E., Morganti M., Saleri R., Martelli P. 2011 
International PRRS Symposium (IPRRS Symposium) – Chicago, USA, 2-3 December 
2011, 33. 
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Publications 
 
1) Romani A.A., Desenzani S., Morganti M.M., La Monica S., Borghetti A.F.,               
Soliani P., 2009. Zoledronic acid determines S-phase arrest but fails to induce 
apoptosis in cholangiocarcinoma cells. Biochem Pharmacol. 78(2): 133-141. 
 
2) Romani A.A., Desenzani S., Morganti M.M., Baroni M.C., Borghetti A.F., Soliani P., 
2010. The BH3-mimetic ABT-737 targets the apoptotic machinery in 
cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic 
acid. Cancer Chemotherapy and Pharmacology. 67(3): 557-567. 
 
3) Borghetti P., Saleri R., Ferrari L., Morganti M., De Angelis E., Franceschi V., 
Bottarelli E., Martelli P., 2010. Cytokine expression, glucocorticoid and growth 
hormone changes after porcine reproductive and respiratory syndrome virus              
(PRRSV-1) infection in vaccinated and unvaccinated naturally exposed pigs. 
Comparative immunology, microbiology and infectious diseases. 34(2): 143-155. 
 
4) Martelli P., Ferrari L., Morganti M., De Angelis E., Bonilauri P., Guazzetti S., Caleffi 
A., Borghetti P., 2011. One dose of a porcine circovirus 2 subunit vaccine induces 
humoral and cell-mediated immunity and protects against porcine circovirus-
associated disease under field conditions. Vet. Microbiol. 149(3-4): 339-351. 
 
 
 
Articles on revision 
 
1) Borghetti P., Morganti M., Ferrari L., De Angelis E., Saleri R., Cavalli V.,                
Corradi A., Martelli P., 2011. Modulation of pro-inflammatory and immune cytokines 
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